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Abstract 
Topical nanomaterials can enhance the passive diffusion of therapeutic agents into 
biological tissues but the mechanism by which they function is not yet fully understood. 
The aim of this study was to elucidate the interactions between the model drug 
tetracaine and the surfaces of nanomaterials with the view to understand and optimise 
the transmembrane transport process. Tetracaine was observed to form aggregates in 
aqueous solutions in the µM range and this aggregation process changed its 
percutaneous permeation. Nanoparticles co-administered on the membrane surface upon 
drug application were shown to manipulate the drug aggregation, thereby enhancing 
transmembrane transport. Tetracaine adsorbed strongly to the surface of carboxyl-
modified polystyrene nanoparticles (Nano!"#$$%) and minimally to silica nanoparticles 
( Nano!"#! ). The Nano!"#!  enhanced tetracaine transport by 3.6-fold while the Nano!"#$$%  hindered tetracaine transport, leading to the conclusion that a mild 
perturbation of the tetracaine aggregation by a nanoparticle surface produced the most 
interesting effects in terms of transmembrane transport. These results were translated to 
a topical HPMC spray formulation. The co-administration of HPMC tetracaine spray 
formulation with Nano!"#!  enhanced tetracaine transport by 95-fold, improved 
accumulative by 307-fold and reduced the lag time by 15.6-fold when compared to the 
commercially available Ametop. The superiority was attributed to the Nano!"#!breaking of tetracaine aggregates, known to hinder permeation. In addition, 
the decrease in formulation macroviscosity was hypothesized to have reduced drug-
vehicle interactions and thus facilitate permeation. The strategy of utilising 
nanomaterials to manipulate drug aggregation described herein represents a potential 
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J1 Steady state flux of tetracaine from the tetracaine 
J2 Steady state flux of tetracaine from the tetracaine-nanoparticle 
mixture 
J Steady state flux of the solute ∝ Thermodynamic activity of the drug in its vehicle 
h Thickness of the membrane 
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Drug delivery to the skin for both systemic (transdermal) and local (topical) actions has 
an important role in modern clinical practice. This is evident from the fact that the 
transdermal drug delivery market was worth US$ 25 billion in 2013 and it is anticipated 
to surpass US$ 40 billion by 2018 (Reuters, 2014). The systems used for drug delivery 
to the skin include transdermal patches, topical gels and topical spray formulations. For 
numerous drugs, these delivery systems represent an attractive alternative to other 
routes of administration, especially when the clinical condition is located in or close to 
the skin (Brown et al., 2006). For example, unlike the oral route, drug delivery to the 
skin can avoid the drug degradation in the gastrointestinal tract or the first-pass effect of 
the liver, which can metabolise a significant proportion of drugs prior to them reaching 
their site of action. Applying a drug to the skin also offers the possibility of sustained, 
localized and controlled release of drugs. Moreover, drug delivery to the skin is 
typically non-invasive and usually has high rates of patient compliance.  
 
Despite the success of the topical and transdermal delivery products on the market, it is 
known that efficient drug delivery across the skin can be problematic to achieve due to 
the relative impermeability of the stratum corneum (Scheuplein & Blank, 1971). The 
main function of the stratum corneum is to regulate substance exchange, preventing 
exogenous materials from entering while minimising water loss from the body. This 
regulatory role of the skin restricts the type of molecules that can pass into the barrier. 
Researchers have translated this restrictive potential into a range of physicochemical 
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characteristics that drugs that can readily enter the skin by passive diffusion should 
possess – log P of between 1-3 (Hadgraft & Somers, 1956) and molecular weight of < 
500 Da (Bos & Meinardi, 2000). A drug that does not possess these characteristics often 
requires to be administered to the skin tissue in the presence of a penetration 
enhancement strategy in order to try and get enough of the active compound to its site 
of action. Penetration enhancement strategies can be classified into physical and passive 
methods. Some of these approaches, such as electroporation and iontophoresis, have 
been found to be expensive. Other approaches, like chemical penetration enhancers and 
microneedles, disrupt the integrity of the stratum corneum and may present a potential 
issue in terms of tissue infection due to long-term damage of the skin (Williams & 
Barry, 2012). There is not, at present, a single system that can enhance the penetration 
of all compounds across the skin. Hence, an approach has been taken to develop 
numerous systems to account for the different types of molecules that need to be applied 
to the skin. 
 
One skin penetration enhancement method that has received considerable attention into 
the skin is the use of nanomaterials (Prow et al., 2011). However, it is interesting to note 
that despite the vast surfaces areas that nanoparticles generate, drug-nanoparticle 
surface interactions remain poorly characterised in topical pharmaceutical systems. One 
area in which the interaction of drugs with nanoparticle surfaces is particularly 
important is when the drug is prone to molecular aggregation as it is possible that 
nanoparticles could have a role in regulating this process for the purpose of enhancing 
drug delivery into the skin. Therefore, there is a need to investigate further if drug-
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nanoparticle surface interactions are important in the skin penetration enhancement of 
drugs applied using nanomaterials. To achieve that, knowledge of the manner in which 
nanomaterials influence the process of drug absorption is required. The first stage 
towards this goal is to understand the basic physiology of the skin layers and how 
nanoparticles interact with the skin barrier. 
 
1.2 Skin barrier and the potential routes of drug absorption 
 
The skin is the largest and heaviest organ of the human body, accounting for 10% of the 
body mass of an average person and a total area of nearly 2 m2 (Williams, 2003). The 
main functions of the skin are to maintain homeostasis, to sense the external 
environment and to provide a protective barrier against foreign material ingress (Elias, 
1983; Lee et al., 2006; Walters, 2002). This protective function is achieved primarily by 
its highly stratified structure. A comprehensive review of the structure of the skin and 
its barrier functions can be found in the literature and hence, a summary of its properties 
will be provided in this thesis (Barry, 1983; Elias, 1981; Scheuplein & Blank, 1971; 
Williams, 2003).  
 
The skin constitutes 3 main tissue layers – the epidermis, the dermis and the 
hypodermis (Fig. 1.1); each consisting of different cells performing distinct functions. 
The epidermis has a multi-lamellar structure representing the different stages of cell 
differentiation. The stratum corneum, the outermost layer of the skin is treated as a 
separate membrane and the term viable epidermis is used to describe the other 4 
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underlying layers. In addition, there are 3 types of appendages originating from the 
dermis that traverse through the different skin layers – the hair follicle, the sebaceous 
gland and the sweat gland. It is important to understand each of these three layers in 




Figure 1.1. Structure of the skin. Obtained from Williams (2003). 
 
1.2.1 Stratum corneum 
 
The stratum corneum is the final product of the differentiation process, comprising of 
dead keratinized cells, known as corneocytes, interspersed within a lipid rich matrix. It 
has a thickness of 10 to 20 µm when dried (Christophers, 1971; Christophers & 
Kligman, 1964) and 40 µm upon hydration (Blank et al., 1967). The ‘brick-and-mortar’ 
model can explain the stratum corneum structure, with the ‘bricks’ composing of 
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corneocytes connected by corneodesmosomes and the ‘mortar’ consisting of multiple 
lipid layers of ceramides, fatty acids, cholesterol and cholesterol esters (Elias, 1983; 
Michaels et al., 1975). The stratum corneum serves as the rate-limiting barrier of drug 
delivery and is known to exhibit selective permeability, allowing only relatively 
lipophilic compounds to pass, given its lipophilic nature (Scheuplein & Blank, 1971). 
This skin layer accounts for more than 80% of the impermeability of the skin (Cevc, 
1997) and when absent, has been shown to increase the diffusion of small water-soluble 




The epidermis, a stratified squamous epithelium, is 100 to 150 μm thick (Bouwstra et 
al., 2003). It is thinner on the eyelids and thicker on certain body sites such as the palms 
and soles due to friction and weight bearing. Unlike the dermis, blood vessels and nerve 
endings are absent in this skin region and thus, nutrients, waste products and drug 
molecules must permeate across the epidermis, cross the dermo-epidermal layer, in 
order to enter systematic circulation (Williams, 2003). Approximately 95% of the 
epidermis comprises of keratinocytes, which arise from the stratum basale and undergo 
progressive differentiation, known as keratinisation or cornification, while migrating 
towards the stratum corneum. This differentiation process is characterised by the 
formation of keratin and lamellar bodies (responsible for the secretion of stratum 
corneum lipids) and ultimately, the loss of its nuclei and organelles to form corneocytes 
(Fig. 1.2). The main function of keratinocyte differentiation is to maintain the stratum 
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corneum through the replenishment of stratum corneum lipids and corneocytes (Eckert, 
1989). The other 5% of cells present in the epidermis include Langerhans cells, which 
are involved in immunity, melanocytes, which are responsible for skin pigmentation 




Figure 1.2. Epidermis depicting different levels of differentiation of keratinocytes.  




The dermis is 3 to 5 mm thick and it makes up the bulk of the skin (Barry, 1983). The 
predominant cells are fibroblasts found in an interwoven network of fibrous proteins 
(collagen, elastin, reticulin) embedded in the extracellular matrix. The fibroblasts are 
responsible for synthesizing the extracellular matrix. The collagen fibres provide 
structural support while the elastin fibres provide flexibility, cushioning the body from 
stress and strain (Wilkes et al., 1973). The dermis can be further categorised into the 
upper papillary layer and the lower reticular layer. The papillary layer is thin and has 
mainly reticular fibres with lesser amounts of collagen and elastin while the reticular 
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layer is thick and has mainly collagen and elastin networks with smaller amounts of 
reticular fibres (Kanitakis, 2002). 
 
Cells that are involved in immunity and mobilising defence such as macrophages and 
dendritic cells are also present in the dermis (Dragicevic & Maibach, 2015). The dermis 
also incorporates nerve endings, blood vessels and lymphatic vessels. The blood supply 
is responsible for thermal regulation, delivery of oxygen and nutrients to the skin and 
removal of toxins and waste products. The lymphatic system serves to regulate 
interstitial pressure, facilitate immunological responses and waste removal. When 
delivering drug to the skin, it is this maintenance of concentration gradient between the 
applied formulation and the vasculature that provides the driving force for drug 
permeation (Scheuplein & Blank, 1971). Dermal blood flow is responsible for the 
clearance of relatively small solutes (e.g. lidocaine) while the lymphatic flow provides 
clearance for larger molecules (e.g. interferon)(Cross & Roberts, 1993). There are 
appendages found on the human skin that originate in the dermis and will be elaborated 




The hypodermis is the innermost layer of the skin, typically in order of a few 
millimetres, consisting of subcutaneous fat tissues. It is absent in some areas of the body 
such as the eyelids. The main cell type present in the hypodermis is the adipocytes. This 
layer of adipose tissue functions as a thermal insulator for the body, a mechanical 
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cushion against physical shock and a reserve depot of readily available high-energy 




There are three main types of skin appendages that traverse from the dermis to the skin 
surface: hair follicles, sebaceous glands and sweat glands (eccrine or apocrine)(Fig. 
1.3). Hair follicles are found over the entire surface of the skin except for the lips, palms 
and soles. The sebaceous gland associated with the hair follicle produces sebum, 
comprising of free fatty acids, cholesterol, cholesterol esters, squalene (Stewart, 1992). 
The sebum lubricates the skin surface and maintains the skin surface acid mantle of 
approximately pH 5 (Katz & Poulsen, 1971). Eccrine sweat glands are present on most 
of the body (at a density of 200-250 /cm2 of skin)(Szabo, 1962). When stimulated in 
response to heat and emotional stress, the glands secrete sweat, a dilute salt solution at a 
pH around 5. On the other hand, apocrine glands are larger and are limited to specific 
areas of the skin such as the axillae, nipples and ano-genital regions. They open into the 
hair follicle and secrete lipodal and ‘milk’ proteins, which are responsible for producing 
the characteristic odour of sweat (Williams, 2003).  
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Figure 1.3. Target structures of terminal hair follicles depicting the hair follicle (HF), 
outer root sheath (ORS), inner root sheath (IRS), companion layer (CL), fibrous sheath 
(FS), sebaceous gland (SG) and arrector pilli (AP). Obtained from Toll et al. (2004). 
 
Knowledge of the skin barrier and function enables the understanding of the routes of 
drug administration into the skin. This is important because topical drug delivery must 
be understood in terms of the drug properties, the type of formulation, the transport 
route and the site of action in the skin. Only if the principles of drug delivery to this 
unique barrier are understood can a mechanism of penetration enhancement, such as the 
use of nanocarrier, be investigated. Therefore, the subsequent section will elucidate the 
current knowledge regarding the routes of drug entry into the skin in order to 
understand in greater detail the challenges posed when attempting to deliver a topically 
administered drug into the tissue. 
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1.2.6 Routes of drug permeation across the skin 
 
When a therapeutic drug is applied as a formulation to intact skin, the drug goes through 
processes before permeating through the skin. Firstly, the drug incorporated in a vehicle 
has to partition out of the vehicle, onto the surface of the skin. Only drug molecules at 
the vehicle-skin interface can further partition into the outermost layer of the stratum 
corneum and diffuse through the skin. The latter is considered the main barrier to drug 
delivery through the skin. Compounds can traverse the skin by passive diffusion using 
three main pathways (Fig. 1.4): 1) the transcellular pathway, between the corneocytes; 
2) the intercellular pathway, crossing through the corneocytes and the interspersed 
lipids; and 3) the transappendageal pathway (shunt route transport, i.e. hair follicles and 





Figure 1.4. Routes of drug permeation. Obtained from Hadgraft & Lane (2011). 
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In the transcellular pathway, molecules partition into and diffuse across both 
corneocytes and intercellular lipid lamellae. Although this pathway provides a shorter 
route and larger surface area to cross the stratum corneum, the repeated diffusion across 
hydrophilic and lipophilic domains makes the transcellular pathway highly 
unfavourable. As such, the intercellular pathway is the preferred pathway (Albery & 
Hadgraft, 1979; Hadgraft & Guy, 1989). In the intercellular pathway, molecules can 
navigate across the tortuous path within the intercellular lipids surrounding the 
corneocytes (Menon & Ghadially, 1997; Michaels et al., 1975). After the molecules 
penetrate the stratum corneum, they arrive at the stratum corneum/viable epidermis 
interface where they must partition and diffuse into the hydrophilic viable epidermal 
tissue before reaching the epidermis/dermis junction. At this junction, the molecule has 
to repeat the partition and diffusion process into a more hydrophilic dermis to progress 
any further.  
 
The transappendageal pathway provides a penetration route that circumvents transport 
across the stratum corneum barrier. It makes use of hydrophilic natural openings that 
can be up to a few microns in size (Pegoraro et al., 2012). However, as the skin 
appendages occupy only 0.1% of the skin surface (Scheuple, 1967), it is widely 
considered that this route of entry into the skin is not the principle mechanism whereby 
most topically applied drugs penetrate into the tissue. The transepidermal (transcellular 
and intercellular) pathway is usually regarded the principal means of entry for 
therapeutic agents (Williams, 2003). However, it would be over simplistic to assume 
that the transappendageal pathway does not play a role in drug permeation because it is 
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feasible that the 3 routes of permeation mentioned herein can occur concomitantly and 
the relative contribution is determined by several factors including the nature of the 
permeant, the components of the formulation, the type of administration system and of 
the mechanism of action of enhancement strategies that are applied to the delivery 
system. 
 
1.2.7 Influence of compound physicochemical properties on drug transport 
 
The drug permeation route is dependent on the size and polarity of the drug. Polar or 
hydrophilic compounds are more likely to traverse through the transcellular pathway 
(Barbero & Frasch, 2006), while lipophilic compounds are more likely to be transported 
via the intercellular pathway (Abraham et al., 1995). Lipophilic drugs may be retained 
in the lipophilic stratum corneum and partitioning into the more hydrophilic viable 
epidermis may be deterred, thus making the stratum corneum the rate-limiting step for 
the drugs. On the other hand, the transappendageal pathway plays a more important role 
for hydrophilic molecules such as caffeine (Otberg et al., 2008), which would encounter 
more resistance from the stratum corneum (Barry, 1987). The transappendageal 
pathway also contributes to the delivery of vesicular structures through the skin. It is 
debatable if vesicles can penetrate the stratum corneum intact, but these structures are 
known to penetrate into the pilosebaceous units (Lauer et al., 1996).   
 
Knowledge regarding the routes of delivery through the skin can help understand the 
movement of drug molecules applied to the surface of the tissue as a topical formulation 
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into the underlying barrier. However, it is important to appreciate that the means by 
which topical products are formulated can alter the route taken by drugs as the relative 
importance of each pathway can change depending on the manner the administration 
method applied the drugs to the skin. For example, the transappendageal pathway is 
central in iontophoretic drug delivery, which uses electrical charge to drive molecules 
into the skin. Drugs are more likely to penetrate into the appendages because they 
provide less resistance than the stratum corneum.   Therefore, information regarding the 
formulation properties of a topical product must be integrated with the route of delivery 
into the skin and the site of action of the drug. To help understand how formulations act 
to deliver molecules into the skin, the mathematical models that describe this process 
are usually employed. 
 
1.3 Mathematical models 
 
Drug permeation through the skin often requires the drug to partition and diffuse 
through the vehicle, stratum corneum and epidermis, as is the case for a wide range of 
drugs. Their site of action is within the viable cells of the skin. This process is 
dependent on a number of factors related to the physical, chemical and biological 
properties of the molecules and the skin tissue. To try and simplify the multitude of 
parameters that can influence skin drug delivery, researchers have attempted to develop 
a series of mathematical models that simplify the process, usually by considering only 
the most important elements in the permeation process. 
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1.3.1 Fick’s 1st law 
 
The definition of the stratum corneum as the main barrier has allowed several relatively 
simple mathematical relationships to describe the drug permeation process because the 
skin is simplified to represent a single homogenous membrane. As the transport through 
this barrier is passive, i.e., it is energy independent, diffusion through the skin it is 
underpinned by Fick’s 1st Law (Moser et al., 2001): 
 J = −D   !!!!                                           (Equation 1.1) 
  
where J is the steady state flux of the solute, D is the average diffusion coefficient for 
the solute in the membrane, !!!! is the concentration gradient, C is the concentration and x 
is the space coordinate measured normal to the section. The most common form of 
Fick’s law is in its integrated form (Scheuplein & Blank, 1971): 
 J = !"∆!!!                                            (Equation 1.2) 
 
where 𝐾  is the partition coefficient of the solute between the skin and vehicle, ∆𝐶! is the 
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The permeability coefficient (𝑘!) of a permeant through a membrane can be expressed 
as: 
 k! = !"!      (Equation 1.3) 
 
which can be substituted into the previous equation (Eq. 1.3) to give: 
 J = k!  ∆C!    (Equation 1.4) 
 
An appreciation of these equations enables the process of drug permeation to be 
described. The parameters that influence them have to be identified and consequently, 
the means by which penetration enhancement strategies act to accelerate molecule entry 
into the skin can be investigated using these models. There is however, like in all areas 
of science, debate in the published literature regarding the most important parameters in 
the equations and this can be exemplified by the Higuchi’s equation. 
 
1.3.2 Thermodynamic activity and the Higuchi’s equation 
 
In 1960, Higuchi adapted Fick’s 1st Law in order to highlight the importance of drug 
thermodynamic activity (Higuchi, 1960), which was, 
 J =   ∝! !!     (Equation 1.5) 
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where ∝ is the thermodynamic activity of the drug in its vehicle and  𝛾 is the effective 
activity coefficient of the agent in the skin barrier phase. This laid down a seminal 
principle for a number of modern theories to follow in subsequent years. This approach 
stated that an ideal saturated system, where the drug solute is dissolved in a solution that 
is in equilibrium with the solid state exhibiting a thermodynamic activity of unity (∝ = 
1), should result in the same penetration rate irrespective of the vehicle composition or 
drug concentration. There are three important assumptions made in Higuchi’s idealised 
scenario – 1) the system is homogenous. This applies to the drug, vehicle and 
membrane and assumes there are no interactions between the constituents (drug, 
vehicle, polymer etc.) and the membrane; 2) the thermodynamic activity of the drug in 
the vehicle is homogenous throughout the system; 3) the membrane determines the rate 
of drug permeation. In practice, very few topically applied pharmaceutical systems meet 
all of these criteria, but with consideration of drug-vehicle-membrane interactions, it is 
possible to use this relationship in a comparative manner to analyse transport data 
(Walters, 2002). 
 
1.4 Enhancement strategies 
 
Increased understanding of the skin barrier and the drug permeation models have led to 
an emergence of different approaches to overcome the stratum corneum barrier and 
enhance drug delivery across the skin. The strategies that have been developed can be 
classified according to their mode of action, i.e. physical and passive approaches (Fig. 
1.5).   
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Figure 1.5. General skin penetration enhancement strategies obtained from Hadgraft & 
Lane (2011). 
 
Drug transport can be increased by physical means through: 1) increasing skin 
permeability via the provision of a transport driving force or in some circumstances, 
disruption of the stratum corneum lipid bilayers (e.g. ultrasound, iontophoresis, 
electroporation); 2) bypassing the stratum corneum barrier (e.g. microneedles, jet 
injection); and 3) removing the stratum corneum (e.g. thermal ablation). However, these 
approaches can be expensive, difficult to self-administer and present the potential for 
significant side effects due to the damage induced to the stratum corneum (Williams & 
Barry, 2012). 
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Passive enhancement strategies seek to manipulate the permeation characteristics of the 
drug by optimising the partition coefficient (K) and the diffusion coefficient (D) of the 
permeating molecule via the co-administration of formulation excipients that act as 
chemical penetration enhancers. The changes brought about by the formulation 
excipients can be induced through the manipulation of the skin properties or by the 
changes in the physical interactions in the formulation. Both these penetration 
enhancement methods can have potential drawbacks. For example, if chemical 
penetration enhancers elicit their activity by fluidizing the stratum corneum lipid, this 
leads to a temporal decrease in its barrier function and can change its hydration, which 
can induce skin sensitization, irritation and toxicity (Prausnitz & Langer, 2008).  
 
An ideal drug enhancement strategy would increase drug permeation without perturbing 
the skin, be economical, safe to use and easy to apply. One penetration enhancement 




According to the British Standards Institution (2007), the term ‘nanoscale’ encompasses 
structures with a size range of 1-100 nm. In drug delivery, the size of nanomaterials 
ranges from a few nm to 1000 nm (Fig 1.6)(Donnelly & Singh, 2015). Between 2010 
and 2013, the emerging nanotechnology market has increased 40-45% per year from 
$339 billion in 2010 to more than $1 trillion in 2013 (National Science Foundation, 
2014). In 1986, L’Oreal (online) introduced the first nanometric skin product to the 
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world, the Niosome, which proved to be an efficient transporter of active ingredients 
such as retinol or vitamin E and more companies have followed suit. Nanomaterials can 
be categorised into vesicular carriers and rigid nanoparticles. Vesicular carriers stem 
from conventional liposomes and have been developed to include niosomes, ethosomes 
and transfersomes to name a few. Rigid nanoparticles can be further classified based on 
their materials into lipid, polymeric, metal and ceramics. To understand how these 
nanomaterials enhance the topical delivery of agents into the skin, one must understand 
how the different nanomaterials are classified, produced and by which important 




Figure 1.6. Different types of nanomaterials depicting multilamellar vesicle (MLV), 
large unilamellar vesicle (LUV), small unilamellar vesicle (SUV), solid lipid 
nanoparticle (SLN), nanostructured lipid carrier (NLC), nanoemulsion, nanoparticle, 
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1.5.1 Types of nanomaterials 
1.5.1.1 Vesicular carriers 
 
Liposomes are vesicular carriers consisting of phospholipids and cholesterol. These 
vesicle structures are typically 10-1000 nm in size (Walters, 2002). By varying the 
composition of the lipid and method of preparation, the physicochemical properties of 
liposomes (size, charge and deformability) can be changed to suit the needs of 
application. Liposomes can be formed of one or more concentric bilayers forming 
spherical colloids with an enclosed inner aqueous core (Mezei & Gulasekharam, 1980). 
Both hydrophilic and hydrophobic drugs can be incorporated into the liposome, with the 
former located in the aqueous space inside the colloid, in contact with the polar head 
region (hydrophilic moiety) of the liposome, and the later solubilised in the lipophilic 
bilayers of the liposome. Conventional liposomes can be further developed into new 
types. An exhaustive list has recently been compiled by Wagner and Vorauer-Uhl 
(2011). 
 
1.5.1.2 Lipid nanoparticles 
 
Lipid nanoparticles may be categorised into solid lipid nanoparticles (SLN) and 
nanostructured lipid carriers (NLC) and can be distinguished based on their solid matrix 
organization. SLN comprise of a single lipid that solidifies at room temperature and 
have crystalline matrices. The drug is either entrapped in the core or dispersed in the 
solid lipid matrix. The crystalline matrix of the SLN gets perturbed when large amounts 
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of drug are added and thus, drug loading within the matrix is limited. The drug 
molecules in such cases may adsorb onto the surface or separate from the particles 
(Fireman et al., 2011). However, NLCs are made of both solid lipids and liquid lipids 
that blend into a distorted crystalline lattice structure when solidified. The drug is 
incorporated into its core and the average particle size of these nanomaterials is 50-1000 
nm (Schäfer-Korting et al., 2007). NLCs were considered as an improvement of the 
SLNs, as they exhibited a higher loading capacity of drugs, required lesser water to 
encapsulate the drug and were less likely to expel its contents during storage (Mehnert 
& Mader, 2001). 
 
1.5.1.3 Polymeric nanoparticles 
 
The polymeric nanomaterials investigated for skin enhancement strategies include 
polystyrene (PS), poly-lactic acid (PLA), poly(glycolic-co-lactic-acid)(PLGA), poly(e-
caprolactone)(PCL) and dendrimers (Guterres et al., 2007; Valenta & Auner, 2004). 
Non-biodegradable polymers, such as PS, have been shown to encapsulate the active 
ingredient, penetrate into the superficial layers of the stratum corneum and release its 
contents into deeper skin layers (Alvarez-Roman et al., 2004a).  
 
Biodegradable polymers, i.e. PLA, PLGA and PCL, exhibit excellent biocompatibility 
and degrade naturally, avoiding the potential cytotoxicity that their non-biodegradable 
counterparts present (Kumari et al., 2010). Based on their composition, these materials 
can be further categorised into nanocapsules or nanospheres. Nanocapsules contain oil 
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and have a vesicular structure, while nanospheres have a matrix organisation of 
polymers (Guterres, Alves et al., 2007). The drug can be entrapped within or adsorbed 
on the surface of both types of nanoparticles.  
 
1.5.1.4 Metal oxide nanoparticles 
 
Metal oxide nanomaterials can be used to administer drugs to the skin. This has a basis 
in the fact that metal oxides (i.e. titanium oxide and zinc oxide) are commonly used to 
protect the skin against UV damage due to their ability to scatter light. They are usually 
coated with aluminium oxide, silica dioxide or silicon oils to increase dispersion 
stability, resulting in a size of about several mm for titanium oxide and 30 to 200 nm for 
zinc oxide (Baroli, 2010b). Sunscreen formulations should remain on the skin surfaces 
to scatter light and not penetrate into the deeper layers. Gontier et al. (2008) used 
transmission electron microscopy and scanning transmission ion microscopy to 
investigate the penetration abilities of titanium oxides ranging from 20 to 100 nm using 
different skin samples such as porcine skin and healthy human skin. The authors 
concluded that titanium oxides nanoparticles are confined within the first 3 to 5 
corneocyte layers of the stratum corneum. In an earlier study by Pflucker et al. (2001) 
using electron microscopy and light microscopy visualisation, titanium dioxide with 
different surface characteristics ranging from 20-100 nm were found deposited on the 
outermost surface of the stratum corneum and were absent in deeper layers of the 
stratum corneum and beyond. A similar observation was reported using titanium oxide 
of the same size range (20-100 nm) using different surface coatings (Schulz et al., 
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2002). Transmission electron microscopy and particle-induced-X-ray emission analysis 
of 20 nm titanium oxide indicated that 90% of the titanium oxide particles were 
recovered in the stratum corneum and the rest were localized in the furrows and opened 
infundibulum of the skin, suggesting some importance of the transfollicular route 
(Mavon et al., 2007). The most important investigation to date was the series of in vivo 
and in vitro studies performed by the EU Scientific Committee on Cosmetics and Non-
Food Products (SCCNFP) in 2000 on titanium oxide within 10 to 1000 nm. All the 
studies concluded that titanium oxide nanoparticles are confined on the skin surface or 
on the outer layer of the stratum corneum and do not penetrate into the living skin. Zinc 
oxide nanoparticles, the other nanoparticle often used in sunscreens, are also impeded 
by the stratum corneum. Roberts et al. (2008) demonstrated 30 nm zinc oxide particles 
did not penetrate into the human skin through in vitro and in vivo techniques using 
multiphoton tomography. This is in accordance with the results obtained by Cross et al. 
(2007) using transmission electron microscopy to observe the in vitro penetration of 
zinc oxide of approximately 30 nm.  All the above reports suggest that metal 
nanoparticles are unlikely to penetrate the stratum corneum.  
 
1.5.2 Nanomaterial-facilitated drug penetration across the skin 
 
The wide number of studies that have reported that nanomaterials enhance the 
permeation of drugs across the skin has drawn attention to their mode of action (Table 
1.1). For example, podophyllotoxin-loaded SLNs with an average diameter of 35 to 210 
nm demonstrated a ~4-fold increase in drug permeation as compared to their 
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hydroalcohol counterparts with no nanoparticles (Chen et al., 2006). A 3.45-fold 
increase in drug flux permeation from triptolide loaded SLNs as compared to aqueous 
solutions was also observed (Mei et al., 2003). Adapalene-loaded PLGA particles with 
the topical aqueous gel required 10-fold less concentration were also shown to achieve 
the same pharmacological activity as that without nanoparticles (Rolland et al., 1993).  
 
There are several crucial questions that arise in understanding the enhancement 
mechanism. Firstly, does the nanomaterial stay on the surface and release its contents 
into the skin or does it penetrate into the skin and release its contents? If so, does the 
nanomaterial penetrate intact? In order to answer these questions, a review on 
nanomaterial penetration through the skin is important (Table 1.2).  
 
Some investigations have shown that nanoparticles are able to penetrate through the 
skin. For example, Cevc and Blume (1992) suggested the intact permeation of elastic 
deformable liposomes (transfersomes) into the dermis layer. Baroli et al. (2007) 
demonstrated that rigid magnetic nanoparticles smaller than 10 nm can penetrate into 
the stratum corneum. Ryman-Rasmussen et al. (2006) also showed that quantum dots 
with a particle size of 4.6 to 12 nm penetrated into the epidermis and dermis layers of 
intact porcine skin. However, these studies focus on very small nanomaterials. The 
majority of nanomaterials used to facilitate molecular penetration into the skin involves 
objects with a size of greater than 20 nm and there is a wealth of data that suggest that 
these materials do not penetrate beyond the superficial layers of the stratum corneum 
into the deeper living tissue (viable epidermis and dermis)(Table 1.2). 
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Particle type Diameter (nm) Skin type Permeation  References 




4.6-12 Porcine Yes (Ryman-Rasmussen et 
al., 2006) 
TiO2 20-50 Human No (Pflucker, Wendel et 
al., 2001) 
TiO2 20-100 Human No (Schulz, Hohenberg et 
al., 2002) 
TiO2 30 Porcine No (Gamer et al., 2006) 
TiO2 20 Human No (Stracke et al., 2006) 
TiO2 20 Human No (Mavon, Miquel et al., 
2007) 
TiO2 20-100 Porcine, 
human 
No (Gontier, Ynsa et al., 
2008) 
ZnO 80 Porcine No (Gamer, Leibold et al., 
2006) 
ZnO 30 Human No (Cross, Innes et al., 
2007) 
ZnO 20-30 Human No (Zvyagin et al., 2008) 
ZnO 30 Human No (Roberts, Roberts et 
al., 2008) 
PS 20, 200 Porcine  No (Alvarez-Roman et al., 
2004a) 
PS 750-6000 Human No (Toll, Jacobi et al., 
2004) 
PLGA 300 Human No (Stracke, Weiss et al., 
2006) 
PLGA 300 Human No (Luengo et al., 2006) 
PLGA 320 Porcine No (Lademann et al., 
2007) 
PS, PMMA <100  Porcine No (Wu et al., 2009) 
PLA 200-400  Human  No (Rancan et al., 2009) 
 
Table 1.2. Summary of rigid nanomaterial penetration through the skin. 
 
The transappendageal pathway may also play a role in nanomaterial interaction with the 
skin (Fig 1.7)(Blume-Peytavi et al., 2010; Knorr et al., 2009; Meidan, 2010; Schaefer & 
Lademann, 2001). However, the skin barrier extends to include the follicles, albeit it 
allows a recess in its continuum, and they should theoretically prevent nanomaterials 
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from penetrating into the living skin (Langbein et al., 2002; Rancan et al., 2012; Toll, 
Jacobi et al., 2004). Nevertheless, hair follicles, sweat glands and pores can act to 
encourage nanomaterial accumulation and subsequently drug deposition. Nanomaterials 
are known to aggregate in the hair follicle openings or skin furrows without penetrating 
into living skin (Lademann et al., 1999; Mavon, Miquel et al., 2007). They can be 
stored until cleared by hair growth or sebum production. As clearance in regions of the 
skin are much slower compared to the skin surface due to avoidance from natural 
desquamation, contact and washing on the skin surface, the pores, hair follicles and 
sweat glands provide an excellent depot for the drugs (Lademann et al., 2005; 
Lademann et al., 2007; Schaefer & Lademann, 2001). The penetration of nanomaterials 
in the hair follicle is also size dependent, with smaller nanomaterials penetrating deeper 
into the hair follicle (Alvarez-Roman et al., 2004a; Toll, Jacobi et al., 2004; Vogt et al., 
2006). It is thought that the hair follicle orifices need to be open and this can be 
achieved during sebum production and/or active hair growth (Lademann et al., 2001; 




Figure 1.7. Deposition of drug from nanomaterials via the transappendageal pathway. 
Obtained from Dragicevic & Maibach (2015).  
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There is limited data on skin penetration of nanoparticles through diseased or damaged 
skin. Hypothetically, nanoparticles could penetrate through diseased skin lesions more 
efficiently due to the damaged stratum corneum, inflammation and increased 
keratinocyte turnover. However, the current available data seemed to suggest otherwise. 
The Australian Government Therapeutic Goods Administration (2006) highlighted a 
toxicokinetic in vivo assessment of human diseased skin, which did not detect an 
increase in systemic zinc levels following application of zinc oxide nanoparticles. 
Similarly, using a multi-photon imaging technique, Prow et al. (2011) did not observe 
the penetration of 35 nm zinc oxide through skin lesions. The same concern can be 
applied to flexed skin where mechanical stress on the skin can make the skin more 
permeable for nanoparticles. Tinkle et al. (2003) showed that human skin treated with 1 
µm beads and then flexed for 60 min resulted in dermal penetration of the beads. 
However, the data from the flexing experiment was not reproducible when applied to 35 
nm zinc oxide (Prow et al., 2011). Lademann et al., has also shown no penetration of 
nanoparticles in the stratum corneum after massaging. Overall, the current evidence 
suggests that nanoparticles do not penetrate through the skin, healthy or modified. 
 
Given the increased attention to the use of nanomaterials, concerns have also been 
raised about the possible risks that they may bring. There are mixed reviews on the 
toxicity of nanomaterials. While some data reports that nanomaterials are safe to use, 
others show that the cellular uptake of nanomaterials may eventually perturb cellular 
pathyways and induce toxicity (Nohynek et al., 2007, 2008, Newman et al., 2009, Borm 
et al., 2006., Baroli et al., 2010b, Oberdörster et al., 2005). The latter would raise more 
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concerns if nanoparticles penetrated into viable skin and the weight of current evidence 
show otherwise, that nanoparticles do not penetrate beyond the stratum corneum and 
does not pose a health risk.  
 
1.6 Interpreting nanomaterials drug-facilitated transport using traditional 
skin penetration models 
 
Although the drug enhancement effect of nanomaterials in skin drug delivery is widely 
accepted, the mechanism of permeation enhancement remains unknown (Table 1.2). It 
is possible that small flexible nanomaterials such as ethosomes and transfersomes could 
enhance penetration into the skin by direct entry into the barrier (Honeywell-Nguyen et 
al., 2004). However, it is unlikely that such a mechanism of action applies to rigid solid 
nanomaterials with a size greater than 20 nm, i.e., the nanomaterials most regularly 
employed in drug delivery studies, because they are too large to pass into the skin, as 
discussed in Section 1.5.2. As such, drugs must be released at or near the skin surface 
before they can further permeate the skin. In these cases, enhancement of drug transport 
can be achieved by acting as a drug carrier, modifying the membrane barrier or 
changing the physical drug interactions in the formulation, each of these potential 




Chapter 1: General Introduction 
 








Figure 1.8. Possible mechanisms of nanomaterials. Nanomaterials may A) act as a drug 
carrier and deposit the contents at the skin surface; B) act as a penetration enhancer and 
modify the skin surface such that drugs easily permeate through; C) form an occlusive 
layer or fuses with the skin membrane to enhance drug permeation; or D) penetrate 
through the drug as intact vesicles to deposit the drug in deeper layers of the skin. 
Obtained from El Maghraby et al. (2006). 
 
1.6.1 Action as a drug carrier 
 
Traditionally, larger particles such as microparticles are used as carriers – to load, store 
and release the drug. Nanoparticles can have the same function. When used as a carrier, 
nanomaterials can be used to mask colour and odour (Kuelkamp-Guerreiro et al., 2013; 
Souto et al., 2005), control release of drugs across the membrane (Jenning et al., 2000; 
Puglia et al., 2008) and provide chemical protection through immobilisation of the 
active until release by the particle (Dingler et al., 1999; Trombino et al., 2009). They 
have been proposed to have the potential to target certain cells and can be designed to 
avoid immunogenic pathogens of the body (Fireman, Toledano et al., 2011).  The drug 
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can either be incorporated into or deposited on the surface of the nanomaterial when it 
acts as a carrier.  
 
There are three ways, depending on their ultimate fate, in which nanomaterials may 
deposit their drug into the skin. If, as previously suggested, the nanoparticles remain on 
the skin surface and are unable to cross the impermeable stratum corneum barrier the 
encapsulated drug will be released on the superficial layers of the stratum corneum. 
Subsequent drug transport into the deeper layers of the tissue occurs after the 
nanoparticle contents have been released. This mechanism has been shown using 
confocal laser microscopy (Alvarez-Roman et al., 2004a; Alvarez-Roman, Naik et al., 
2004b).  
 
Alternatively, nanoparticles carriers can accumulate in the shunts available in the 
bottom of the stratum corneum and deposit the drug contents in this region of the skin. 
This encourages drug transport specifically via the transappendageal pathway, which 
provides less resistance compared to the transepidermal pathway (Blume-Peytavi, 
Massoudy et al., 2010; Knorr, Lademann et al., 2009; Lademann, Otberg et al., 2001; 
Schaefer & Lademann, 2001). The transappendageal pathway provides an excellent site 
for accumulation due to its slower clearance and the provision of a shorter diffusion 
distance to the living tissues.  
 
If nanoparticles can penetrate the skin (see earlier example of transfersomes), they can 
partition into the layers of the skin and then release the drugs directly into the tissue 
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(Honeywell-Nguyen & Bouwstra, 2003; Honeywell-Nguyen et al., 2002; Honeywell-
Nguyen et al., 2004). In general, rigid nanomaterials are not expected to enter the 
stratum corneum as intact entities but whether highly deformable nanomaterials able to 
penetrate into the living tissue or even through the stratum corneum intact remains 
debatable.   
 
Despite the potential that nanoparticles have to offer, the use of nanomaterials as a drug 
carrier to administer drugs in a clinical setting is still rare. This may be because if 
nanoparticles are used as a carrier, they are more expensive to manufacture and they 
introduce a second rate-limiting release step into the topical drug delivery process 
(Baroli, 2010a). These nanocarriers also poses challenges in the fact that they can have 
a low loading capacity (Schäfer-Korting, Mehnert et al., 2007), can prematurely releases 
drugs (Zhao et al., 2010) and may result in poor drug release if the affinity between 
drug and the carrier is high. All the disadvantages are diminished if an approach is taken 
to use nano-sized material to control drug aggregation through their surface interactions 
when delivering a drug to the skin. 
 
1.6.2 Nanoparticle modification of the skin barrier 
 
One of the suggested modes of action of nanomaterials is the modification of the skin 
barrier function. This can be achieved by acting as a penetration enhancer, which can 
take the form of adsorption and/or fusion with the stratum corneum. Nanomaterial 
constituents, such as ethanol, non-ionic surfactants and lipid esters, may act as 
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permeation enhancers. These nanomaterial constituents may penetrate into the skin and 
disorganise the stratum corneum lipid matrix to the extent that drugs may permeate 
more easily through the skin. For example, Hofland et al. (1994) investigated the 
permeation of estradiol from liposomes through the human stratum corneum. In order to 
investigate the penetration enhancing effects of the liposomes, stratum corneum were 
treated with empty surfactant carriers prior to application of the estradiol. An increase in 
flux was observed, hinting that penetration-enhancing effect of surfactant molecules 
was important in drug enhancement process. Using freeze fracture electron microscopy, 
the authors continued to study the interactions between liposomal formulations and the 
human stratum corneum (Hofland et al., 1995). The fusion of phospholipid constituents 
of the liposomes and stratum corneum lipids induced ultra-structural changes in the 
deeper layers of the stratum corneum and this modification of the stratum corneum was 
believed to have aided drug permeation through the skin. In another study, El Maghraby 
et al. (1999) demonstrated a 4-fold drug permeation enhancement from skin pre-treated 
with liposomes and a 8-fold enhancement from drug encapsulated liposome, 
emphasising the penetration enhancing effect of nanomaterials through a process of 
membrane barrier disruption.  Fusion with the stratum corneum is another mode of 
action within the remit of modifying the skin barrier that can increase drug partitioning 
into the stratum corneum to facilitate an improvement in drug permeation (Kirjavainen 
et al., 1999).   
 
Another mechanism that nanomaterials may modify the skin barrier is by adsorption to 
the skin to form an occlusive layer (Wissing et al., 2001; Wissing & Muller, 2002; 
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Wissing & Muller, 2003). When nanomaterials adhere to the superficial surface of the 
skin, they can form an adhesive film, which creates occlusion. Smaller nanoparticles are 
better at occluding the skin surface due to their larger surface area (Wissing & Muller, 
2003). The occlusive layer hydrates the skin, resulting in a change in stratum corneum 
structure that facilitates drug permeation through the skin (Wissing, Lippacher et al., 
2001; Wissing & Muller, 2002; Wissing & Muller, 2003). Wissing and Muller (2003) 
observed that nanoparticles smaller than 400 nm demonstrated a 4-fold increase in 
occlusivity compared to microparticles. However, this mechanism will only be 
applicable to very hydrophobic drugs, which use the transcellular pathway e.g. 
corticosteroids, other hydrophilic agents can be retarded by hydration of the stratum 
corneum e.g. caffeine. 
 
1.6.3 Changing physical drug interactions in the formulation 
 
Nanomaterials may also enhance drug permeation through the skin by changing the 
physical interactions of the drug in the applied formulation. One consequence of 
modifying the formulation’s physical interactions with the drug can be an increase in 
drug thermodynamic activity. An increase in thermodynamic activity of a drug in a 
formulation can result in an increase in drug permeability through the skin. The in vitro 
porcine skin permeation experiments of α-tocopherol and α-tocopherol acetate delivered 
by lipid nanoparticles showed a 3.4-fold increase in drug permeation into the stratum 
corneum and 1.3-fold increase in the viable epidermis was attributed to changes in drug 
thermodynamic activity (Fangueiro et al., 2012). In another study, triptolide actives 
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were found to permeate 3.45 times higher through rat skin using solid lipid 
nanoparticles in comparison to their aqueous counterparts as a consequence of changes 
in the drug thermodynamic activity (Mei, Chen et al., 2003). Polymeric nanoparticles 
were also found to increase nimesulide permeation through human skin through the 
same mechanism (Alves et al., 2007).  
 
Clearly, changing the physical interactions of a drug in a formulation presents a 
potential strategy to enhance drug permeation. At present, there seems to be an 
emphasis in the published literature on changing the thermodynamic activity of the 
drug. However, there is more than one way that the control of physical interactions can 
influence drug properties in an effort to enhance skin permeation. One of the less 
explored mechanisms is the concept of modifying drug aggregation. 
 
1.7 Nanomaterial-facilitated control of drug aggregation 
 
There are many ways to optimise skin drug delivery, but the idea of controlling 
molecular aggregation of therapeutic molecules is a concept that has not gained 
significant attention to date. This would suggest that drug-drug interactions are not 
considered to be an important concept in skin delivery, however drug-drug interactions 
are known to occur in formulations applied to the skin (Walters, 2002). A number of 
drugs are amphiphilic and demonstrate the tendency to self-associate at high 
concentrations (Berge et al., 1977).  
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1.7.1 Drug aggregation 
 
Amphiphilic compounds are composed of 2 distinct portions: an ionic or non-ionic 
polar head portion and a hydrophobic portion. When placed in an aqueous solution, 
these compounds can form organised structures, such as micelles, monolayers, bilayers, 
cubic and hexagonal phases, or disorganised structures. The type of structures formed 
depends on their molecular structure. In the pharmaceutical field, simple classical 
surfactants are the most extensively researched for their aggregation properties and their 
biological activity. They are able to interact with membranes, promote lysis, denature 
proteins or disrupt lipids and solubilize within the membrane (Helenius & Simons, 
1975). Surfactants tend to self-associate to form micelles, which are spherical 
aggregates with the hydrophobic portion sequestered from the polar surrounding. In 
1935, Goodeve envisioned a stepwise addition of monomer molecules to existing 
micelles (Wyn-Jones & Gormally, 1983). This aggregation process can be presented in 
the form of several equilibria and equilibration constants or a phase separation process, 
ultimately cumulating to a critical concentration, often known as critical micellar 
concentration (CMC) or the critical aggregation concentration (CAC) depending on the 
structures formed. Beyond this concentration, further addition of monomers form 
aggregates.  Aggregation is a dynamic process, with aggregates forming within a 
microsecond lifetime (Patist et al., 1999). Micelles are usually characterised by their 
CMC, aggregation number, particle size, and hydrophilic-hydrophobic balance 
(Schreier et al., 2000). In some cases, pre-micellar aggregation is investigated (Ernandes 
et al., 1977; Schreier et al., 1978).  
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Amphiphilic drugs present a unique group of aggregates that share certain similarities 
with surfactants and dyes (Wyn-Jones & Gormally, 1983). For example, cationic 
ammonium germicides have structures resembling surfactants and they form spherical 
micelles. On the other hand, phenothiazine tranquilisers have rigid aromatic ring 
systems and form aggregates resembling to the base-to-base stacking of cationic dyes. 
Despite some resemblances, amphiphilic drugs are not identical to surfactant structures 
because they tend to be smaller and more compact molecules. This results in the drug 
aggregation process generally being continuous, unlike the step-wise micellar 
association. Examples of amphiphilic drugs include local anaesthetics, phenothiazine, 
benzodiazepine tranquilizers, antibiotics, tricyclic antidepressants, antihistamines, 
anticholinergics, anti-cancer drugs and non-steroidal anti-inflammatory drugs. Their 
biological and pharmaceutical implications have been comprehensively reviewed by 
Schreier et al. (2000). The molecular aggregation characteristics are dependent on the 
structure of the drug molecules. For example, drugs such as the tricyclic antidepressants 
and phenothiazine have been shown to form micelles and phenanthrene narcotic 
analgesics are known to associate in a non-micellar manner (Wyn-Jones & Gormally, 
1983). Similar to surfactants, amphiphilic drugs are known to aggregate and disrupt 
membranes. 
 
Molecular aggregation is concentration-, temperature-, ionic strength-, and pH-
dependent. As early as 1913, aggregates formed by an increased concentration of 
sodium stearate have been found to exhibit a different conductivity to those of sodium 
acetate (McBain, 1913). Later in 1930, Bury and Davies introduced the term ‘critical 
Chapter 1: General Introduction 
 




X. J. Cai 
39 
concentration for micelles’ and noted the decrease of this CMC with an increase in 
temperature. Drug aggregation is also affected by the ionic strength of the surroundings. 
For example, an increase in aggregation number and a decrease in CMC were observed 
on 5 different drugs (antihistamines, diphenhydramine hydrochloride, 
bromodiphenhydramine hydrochloride, chlorcyclizine hydrochloride and 
diphenylpyraline hydrochloride) when the electrolyte concentration was increased 
(Attwood & Udeala, 1975). Attwood and Natarjan (1981) also observed a higher critical 
micelle concentration at a low pH (0.5-5.5) in 5 different piperazine drugs 
(trifluoperazine, opirpramol, thiopropazate, flupenthixol and clopenthixol). 
 
Aggregation is commonly characterised by determining the CAC or the CMC in the 
case where a micelle is formed. The National Institute of Standards and Technology 
(NIST) have identified 71 methods to determine CMCs, which were measured by 
detecting an abrupt change in physical property such as surface tension, electrical 
conductivity, light scattering, refractive index, osmotic pressure or density (Mukerjee, 
1971).  Due to their small size and dynamic nature, direct examination to look at the 
structures of monomers and aggregates is difficult and indirect measurement methods 
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1.7.2 Influence of aggregation on skin drug delivery 
 
The drug aggregation process, whether by unorganised self-association or by 
incorporation into an organised assembly, such as micelles and emulsions, can affect the 
physicochemical properties of the drug. There has been evidence found to suggest that 
aggregation can result in a pKa shift and a change in the rates and/or mechanism of 
molecular reactions (Schreier, Malheiros et al., 2000). In addition, the impact of drug 
aggregation on membranes has been described. However, in most pharmaceutical 
systems, the consequences of drug aggregation on functional properties, i.e. skin 
transport, are not considered. Expanding the knowledge of drug-drug aggregation is 
particularly important when the therapeutic agents must cross a biological barrier to 
reach their intended site of action. For example, when applied to the skin, aggregation 
has the potential to significantly influence percutaneous penetration particularly through 
changes in the self-diffusion coefficient of the molecules in the application vehicle and 
the tissue interactions upon passage through the skin. 
 
1.7.3 Strategies to de-aggregate drugs 
 
There have been a number of published studies that describe methods to control 
molecular aggregation, but they can be principally categorised into electrolyte, 
surfactants and polymers. Counter-ions associated can form ion-pairs with charged 
drugs and this can have an influence on the association of molecules in the solution 
state. For example, the hydrochloride salt of tripelnnamine appears to form micelles 
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association, but the maleate salt of mepyramine, brompheniramine and 
chlorpheniramine associates to form unorganised structures (Attwood & Udeala, 1975). 
Surfactants have also been used to break up the aggregation of small molecular weight 
agents such as phthalocyanines and larger therapeutic agents such as insulin. As 
surfactants are amphiphilic, they have the characteristics that can readily disrupt the 
self-association process by direct interaction with the molecules (Darwent et al., 1982; 
Rossetti et al., 2011; Shao et al., 1993; Spikes & Bommer, 1986).  
 
The addition of polymers can modify the molecular aggregation of drugs. Pygall et al. 
(2011) noted that different interactions between hydroxypropyl methylcellulose 
(HPMC) and two structurally related drugs, diclofenac sodium and meclofenamic acid 
sodium, occurred upon addition to the applied surfactant of a hydrophobic membrane. 
Contrary to diclofenac sodium, meclofenamate formed self-assembled aggregates on 
addition of HPMC leading to a change in the viscosity, reduction in the vehicle gel 
point and a decrease in the self-diffusion coefficient of the drug. 
 
1.7.4 Using nanomaterials: Benefits of using solid surfaces 
 
Nanoparticles can be used as an alternative to surfactants in that they have surface 
activity and adsorb at the interfacial surface. There has been evidence to show that drug 
penetration increased when nanoparticles were used instead of surfactants to stabilise 
emulsions (Frelichowska, Bolzinger, Pelletier, et al., 2009; Frelichowska, Bolzinger, 
Valour, et al., 2009). Frelichowska et al. (2009) demonstrated that Pickering emulsions 
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(silica particle-stabilised w/o emulsions) exhibited 3-fold higher caffeine flux than 
conventional emulsions (surfactant-stabilised w/o emulsions) even though both vehicles 
had the same physicochemical properties in terms of droplet size and viscosity. 
  
It is proposed that nanoparticles can break up the aggregation of the drug, thus 
improving drug mobility. It is noteworthy that in this project nanoparticles are 
introduced to control the physical interactions of the drug in the topical formulation in 
order to facilitate drug permeation, rather than being used as a drug carrier that 
encapsulates drugs to transport them across the membrane (Fireman, Toledano et al., 
2011; Prow, Grice et al., 2011).  
 
1.8 Aim and scope 
 
The aim of this PhD was to investigate the interactions between the surfaces of 
nanomaterials and co-formulated drugs with a view of designing a novel penetration 
enhancement strategy for drug delivery into the skin. The project hypothesis was that 
the introduction of the nanoparticle at the point of administration to the surface of the 
skin would generate a dynamic system that could break up drug-drug aggregation in a 
manner that could facilitate the temporal increase in drug monomers that could 
permeate across the skin. The project aim was addressed in 4 work phases: 
 
Phase I: Investigation of molecular aggregation characteristics. 
Phase II: Investigation of the effects of nanomaterials on tetracaine permeation 
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Phase II: Investigation of solid-liquid interfacial interactions. 
Phase IV: Generation of in situ self-assembly of nanoparticles upon application to the 
skin 
 
It was anticipated that drug aggregation could influence drug transport and a deeper 
understanding of how to control drug aggregation could be used to improve transport 
through the skin. Tetracaine was selected as a model drug. It exists with a positive 
charge at physiological pH. Its chemical structure has a hydrophilic region (amine 
portion) and a hydrophobic region (aromatic portion)(Fig. 1.9) and this predisposes it to 
self-associate in aqueous solution. At concentrations of more than 1 mM, previous 
literature suggests tetracaine forms an aggregate (Farhadieh et al., 1967; Florence & 
Attwood, 2011; Johnson & Ludlum, 1969). There have been several studies that 
document its CMC, for example, Kitagawa et al. (2004) proposed tetracaine 
hydrochloride had a CMC of 38 mM at 25 °C in an aqueous solution, pH from 4.5 to 
5.7. There appears to be a difference of opinions in the literature as to whether 
tetracaine forms organised micelles (Kitagawa, Oda et al., 2004; Matsuki et al., 1996; 
Shaikh et al., 2011) or random molecular aggregates (Attwood & Fletcher, 1986; 
Farhadieh, Hall et al., 1967). In addition, there is less known about at what 
concentration aggregation commences if indeed a rapid micellisation process is not 
followed. Guerin et al. (1980) and Umemura et al. (1981) suggested that tetracaine were 
thought to exist as free monomers below a concentration of 18 mM using Fourier 
transform infrared spectroscopy (FTIR), but this is close to the limit of detection for this 
technique. 
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Figure 1.9. The chemical structure of tetracaine. Tetracaine is an amphiphilic molecule 
with a hydrophilic region (amine portion) and a hydrophobic region (aromatic portion). 
 
Tetracaine is used clinically as a local anaesthetic for topical application, but it has an 
unusually high penetration lag time. Reducing lag time could improve the drugs 
performance in patients as it is often used before venepuncture or venous cannulation 
(Joint Formulary Committee, online). According to the British National Formulary 
(BNF), the recommended formulation concentration of tetracaine is 0.15 M (Joint 
Formulary Committee, online). At high dosages, tetracaine can lead to hypersensitivity 
reactions and cause harm to the central nervous and cardiovascular systems (Joint 
Formulary Committee, online). 
 
The log P of tetracaine is 2.79, which falls within the ideal range of log P 1 to 3 for skin 
penetration.  Tetracaine is a weak base that is soluble in organic solvents and slightly 
soluble in water. At 32 °C, the temperature of skin surface, protonation of secondary 
amine and tertiary amine occurs at pHs 3.24 and 8.24. Using these pKa values, at pH 4, 
it was predicted that 100% of the tertiary amine would be ionised and 23% of the 
secondary amine would be ionized; at pH 8 it was predicted that 72% of the tertiary 
amine would be ionised and 28% of tetracaine would be unionised. Therefore, it was 
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necessary to investigate whether the drugs aggregation in different pH vehicles had an 
effect on tetracaine permeation through synthetic silicone membranes and porcine 
epidermis (Chapter 2). Once that was established, the effects of nanomaterials on 
tetracaine permeation were quantified (Chapter 3) and then the nanomaterial-drug 
interactions were measured (Chapter 4). After examining the effects of nanomaterials 
on permeation, the nanomaterial with the highest enhancement was selected for the 
development of a HPMC gel (Chapter 5). 










Influence of Tetracaine Aggregation on its 








Chapter 2: Influence of tetracaine aggregation on its passive transmembrane permeation 
 








The excipients that are used to produce topical pharmaceutical products applied to the 
skin are often termed ‘inert’. This definition refers to the fact that the excipients have no 
pharmacological action in themselves, but most excipients are far from ‘inert’ when 
considering the manner in which they modulate the behaviour of a drug when it is 
formulated as a medicine. For example, drug-vehicle interactions in topical products 
have been shown to have a significant influence on their ability to deliver actives into 
the skin (Benaouda, Brown, Ganguly, et al., 2012; Zhang et al., 2012). In topical 
products, a degree of physical interactions between the active and the vehicle must 
occur to facilitate solubilisation of the drug, but if the physical interactions are too 
strong, drug release from the product after application can be hindered (Benaouda, 
Brown, Martin, et al., 2012).  
 
Drug-drug interactions are in equilibrium with drug-vehicle interactions in 
pharmaceutical products and therefore, drug-drug interactions also have the potential to 
modify the performance of a medicine. Several therapeutic agents formulated in topical 
products that are applied to the skin are known to exhibit strong drug-drug interactions, 
which can lead to aggregation in the solution state (Attwood, 1995; Schreier, Malheiros 
et al., 2000; Wyn-Jones & Gormally, 1983). Molecular aggregation is known to modify 
the physicochemical properties of the drug such as lipophilicity, molecular size, degree 
of ionisation, hydrogen bonding and these physicochemical properties can influence 
drug permeation (Bos & Meinardi, 2000; Potts & Guy, 1992; 1995; Shore et al., 1957). 
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Therefore, it would seem logical that molecular aggregation would influence the 
performance of topically applied products. However, the information in the literature 
regarding the potential of drug-drug interactions to modify drug penetration into the 
skin remains very limited. 
 
Molecular aggregation, using simple surfactants as models, is known to influence solute 
transport across the membrane, but even with these relatively simple surfactant 
structures, it is unclear if only the monomer penetrates through the membrane (Charman 
et al., 1991; James-Smith et al., 2011; Mikkelson et al., 1980) or both the monomer and 
the aggregate penetrate the membrane (Moore, Puvvada, et al., 2003; Moore, Shiloach, 
et al., 2003). In addition, given the small size and dynamic nature of surfactant 
interactions, understanding the equilibrium between the monomer structures and 
aggregates is difficult and hence it is usually only measured by indirect analytical 
methods (Mukerjee, 1971). These problems are amplified when applied to drugs 
because they demonstrate more heterogeneous aggregation patterns compared to 
surfactants.  
 
The aim of this chapter was to characterise the molecular aggregation of a model drug 
that is used for topical administration to the skin, tetracaine, so as to better understand 
the influence of the molecular aggregation process on transmembrane transport. It was 
anticipated that this would provide information to determine if nanomaterials could 
control tetracaine aggregation and this would help in the overall PhD goal of developing 
a nanomaterial formulation that enhances drug permeation. Aggregation is ionisation- 
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dependent (Attwood & Natarajan, 1981) and hence, tetracaine aggregation at pH 4 and 
8 was determined in order to investigate the influence of tetracaine ionisation on 
aggregate formation, and subsequently on tetracaine permeation. Parameters known to 
affect aggregation such as temperature, pH and solvent environment were tightly 
controlled in all the experiments and the concentration of the model drug was changed 
in order to try and form different types of aggregates. The tetracaine aggregates were 
characterised by photon correlation spectroscopy, fluorescence spectroscopy and FTIR 
The drug transport was studied using a porcine epidermis and a model membrane to 
understand the manner in which aggregation influence transport through barriers with 
and without the potential for follicular transport.  
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Material Grade Company 
Tetracaine  Free base, ≥ 98% Sigma Aldrich, UK 
Hydrochloric acid (HCl) Fuming 37% Sigma Aldrich, UK 
Deuterium oxide 99.9 atom % D Sigma Aldrich, UK 
Phosphate buffered saline  Tablets, pH 7.4, 0.172 M Oxoid Ltd, UK 
De-ionised water Electrical conductivity  
0.5-1 µS 




Anhydrous, ≥ 99% Sigma Aldrich, UK 
 
Acetic acid ACS reagent, ≥ 99.7% Sigma Aldrich, UK 
Acetonitrile High performance liquid 
chromatography (HPLC) grade 
Fisher Scientific, UK 
 
Methanol HPLC grade Fisher Scientific, UK 
Water HPLC grade Fisher Scientific, UK 
Silicone membrane  Thickness of 0.12 and 0.25 mm GBUK Healthcare, UK 
 
Table 2.1. Materials used in Chapter 2. 
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2.3 Methods 
2.3.1 Test sample preparation 
 
Tetracaine solutions were prepared and adjusted to pH 4.0 or 8.0 using HCl and 
equilibrated at 32°C unless stated otherwise. Solutions were stirred for at least 24 h and 
the pH rechecked prior to analysis to ensure they were at equilibrium.  
 
2.3.2 Photon correlation spectroscopy  
 
The derived count rates were analysed by photon correlation spectroscopy (Malvern 
Nanoseries Zetasizer ZEN3600, Malvern Instruments Ltd, UK). Detection of the light 
scattering signal was achieved at a 173° backscattering angle with samples equilibrated 
at 32°C using water as a dispersant (refractive index 1.33, viscosity 0.8872 cP). Each 
measurement comprised of 10-14 runs. Triplicates of each sample were assessed.  
 
2.3.3 Fluorescence spectroscopy 
 
Fluorescence emission spectra were recorded using a fluorescence spectrometer fitted 
with a Xenon pulse lamp (Varian Cary Eclipse Fluorescence Spectrometer, Agilent 
Technologies, UK). A Quartz fluorescence cell with a 3 mm path length (Helima 
Fluorescence Cell, Helima UK Ltd., UK) was used unless specified. Excitation and 
emission slits were fixed at 5 nm. In all measurements, the excitation wavelength was 
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set at 310 nm. The samples were scanned from 320 to 450 nm at a wavelength scan rate 
of 120 nm/min with a photomultiplier tube (PMT) detector gain of 600 V. The data 
were smoothed with a Savitzky Golay function filter size 25 using the Cary Eclipse 
software. The experiments were performed at a temperature of 32°C. 
 
2.3.4 Critical aggregation concentration (CAC) analysis 
 
The CAC was defined as the concentration of molecules at which deviations from 
linearity of the concentration vs. fluorescence intensity graph occurred. Two methods 
were used to identify the CACs and their values were compared (Khan & Shah, 2008). 
In the first method, a second derivative function was applied to the data using OriginPro 
(OriginPro version 8.6, Origin Lab Corporation, US). The data was fitted non-linearly 
before a Gaussian distribution function was applied to highlight the critical points, i.e. 
the regions where local minimum or maximum occurred. In the second method, the 
intersection of 2 linear slopes was determined.  
 
2.3.5 FTIR analysis 
 
Deuterated water (D2O, Sigma Aldrich, UK) was employed in the infrared analysis of 
the tetracaine solutions as it dampened the solvent signal in the 1700 to 1300 cm-1 and 
3000 to 2850 cm-1 ranges. The samples were loaded into a demountable universal 
transmission cell system (Omni-Cell, Specac Ltd, UK) fitted with calcium fluoride 
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(CaF2) windows and a 25 µm Mylar spacer (Specac Ltd., UK). The pHs of the 
tetracaine solutions were maintained using deuterium chloride (DCl). All spectra were 
produced using 32 scans collected at a spectral resolution of 4 cm-1. The data was 
recorded using a Spectrum One spectrometer (Perkin-Elmer Ltd., UK) and analysed 
with Spectrum software (version 10, Perkin-Elmer Ltd., UK). 
 
2.3.6 Tetracaine transport studies 
 
Two barriers were employed for the transport studies, a silicone membrane (0.12 and 
0.25 mm, GBUK Healthcare, UK, no pre-treatment required) and a porcine epidermis. 
Fresh white adult porcine ears were obtained from a local abattoir (Evans and Sons, 
UK). Damaged ears were discarded. After cleaning with deionized water and wiping the 
residue with clean wipes, visible hairs were trimmed carefully. The preparation of 
epidermal porcine skin was carried out by heat separation (Kligman & Christophel, 
1963). Porcine skin was immersed and gently stirred in deionised water at 60°C for 1 
min. After removal from the deionized water, the skin was put on a corkboard with the 
dermal side down and the epidermis was carefully separated from the dermis with 
tweezers. The separated epidermis was washed with deionized water and floated on 
filter paper (Whatman no. 1, UK) to act as a support. The samples were wrapped in 
aluminium foil and stored at -20°C for a maximum of up to 1 month (Harrison et al., 
1984). The samples were thawed before use.  
 
The transport studies were carried out using upright individually calibrated Franz 
Chapter 2: Influence of tetracaine aggregation on its passive transmembrane permeation 
 




X. J. Cai 
54 
diffusion cells with an average surface area of 2.1 ± 0.1 cm2 and receptor compartment 
volume of 9.2 ± 0.5 mL. The barrier was cut, mounted and sealed with parafilm 
between two chambers of the glass diffusion cell with a 13 mm magnetic flea in the 
receiver chamber. The cells were inverted and filled with previously filtered and 
sonicated receiver fluid. pH 4.0 and 8.0 water adjusted with HCl were used as a receiver 
fluid for the silicone membrane transport studies to investigate the transport of 
tetracaine through a hydrophobic barrier. Phosphate buffered saline (pH 7.4) was 
employed as a receiver fluid for the porcine epidermis transport studies to mimic the 
skin environment. Sink conditions were maintained throughout the transport studies 
(drug concentration in the receiver fluid does not exceed 10% of its saturated 
solubility). The saturated solubility of tetracaine was (1.05 ± 0.04) M in pH 4 water and 
(6.29 ± 0.07) mM in pH 8 water and (7.16 ± 0.05) mM in phosphate buffered saline. 
The transport studies were performed on a submergible magnetic stirrer plate in a pre-
heated water bath set at 37°C to provide a membrane surface temperature of 32°C. After 
cell equilibration for 1 h, the cells were checked for leaks by inversion and visual 
inspection for back diffusion. Infinite doses of tetracaine solutions (1 mL) were applied 
uniformly to the surface of each membrane and the donor compartment was covered 
with a parafilm to minimise donor phase evaporation. In this chapter, 10 µM and 
saturated concentration of tetracaine were applied on the porcine epidermis while 
different concentrations of tetracaine at pH 4 (Table 2.3) and pH 8 (Table 2.4) were 
applied on the silicone membrane to understand the permeability through a non-porous 
hydrophobic membrane. At predetermined time intervals, 1 mL aliquots were removed 
from the receiver phase and replaced with fresh receiver fluid to keep the liquid volume 
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in the receiver compartment constant. The collected samples were analysed by HPLC.  
A total of 5 replicates of each experiment were performed.  
 
Cumulative amounts of drug (ng) penetrating the unit surface of the membrane area 
(cm2) were corrected for sample removal and plotted against time (h). The steady-state 
flux (J) was calculated from the slope of the linear portion of the curve  
(R2 ≥ 0.98), using at least 4 points with values above the assay limit of quantification 
(LOQ). The permeability coefficient of tetracaine was calculated using equation 2.1 
(Williams, 2003): k! =    !!!                                               (Equation 2.1)               
 
where J represents the flux, kp is the permeability coefficient of the permeant across the 
membrane and Cv is the concentration of the drug in the vehicle.  
 
2.3.7 Tetracaine quantification 
 
The quantification of tetracaine was performed using a reverse-phase HPLC system 
consisting of a pump with autosampler (Hewett-Packard series 1050, Agilent 
Technologies UK Ltd., UK) connected to a fluorescence detector (Shimadzu detector 
RF-551, Shimadzu corp., Japan). The system was controlled via a computer with 
Chromeleon software (Dionex Corp., USA), which was also used to record and interpret 
the analytical data. The mobile phase comprised acetonitrile-methanol-acetate buffer 
(0.1 M)(25:25:50 (v/v), pH 5.1) set at a flow rate of 1.0 mL.min-1. Tetracaine was 
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separated using a Luna 3 µm C18(2)(150 X 4.6 mm) stationary phase (Phenomenex, 
UK) at room temperature with a 100 µL injection volume and the fluorescence detection 
at an excitation wavelength of 310 nm and an emission wavelength of 372 nm. The 
retention time for tetracaine was 4.2 min. The calibration curves were constructed on 
the basis of the peak area measurements using standard solutions of known tetracaine 
concentrations dissolved in an identical fluid as the receiver phase for the transport 
studies. The assay was shown to be “fit for purpose” in terms of sensitivity (LOD – 4.08 
ng/mL, LOQ – 74 ng/mL, n=25), precision (6% CV), and linearity (R2 ≥ 0.99).  
 
2.3.8 Statistical analysis 
 
All values were expressed as their mean ± standard deviation (SD). The statistical 
analysis of data was performed using the statistical package for social sciences, SPSS 
version 21, (IBM Corp., USA) with a significance level of 0.05. The normality (Sapiro-
Wilk) and homogeneity of variances (Levene’s test) of the data were assessed prior to 
statistical analysis. Transport data were analysed statistically using one-way analysis of 
variance (ANOVA) tests for normally distributed data and a non-parametric Kruskal-
Wallis tests for non-Gaussian distributed data. Post hoc comparisons of the means of 
individual groups were performed when appropriate using Dunnet’s test for normal 
distributed data and Games Howell test for non-Gaussian distributed data.  For all pair-
wise comparison of means, Student’s independent t-test or Mann-Whitney test was 
applied. Data were presented using OriginPro software (OriginPro version 8.6, 
OriginLab Corporation, US). 
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2.4 Results 
2.4.1 Fluorescence spectroscopy method development 
 
Fluorescence spectroscopy was used to confirm the concentration at which tetracaine 
aggregated in the µM concentration range (see Section 2.4.2 for the results). However, 
as fluorescence is a very sensitive technique that can be influenced by a number of 
experimental parameters, the method was initially tested and developed for its intended 
purpose prior to use. The solvent (pH 4 water) showed the Raman peak of water at 346 
nm (Fig 2.1), which was in the correct location according to theoretical calculations 
using an excitation wavelength of 310 nm (Lawaetz & Stedmon, 2009). The tetracaine 
in pH 4 water solutions emitted a fluorescence signal at 372 nm (Fig. 2.1).  
 
In this study, the temperature and pH of the system were maintained. Moreover, the 
system was chemically stable over 6 days and the effect of ion pairing was not 
significant (Fig. 2.1). Although an increase in fluorescence intensity was observed as 
the temperature increased, an analysis of the data illustrated similar aggregation 
characteristics in terms of CACs. 
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Figure 2.1. A) The fluorescence spectrum of tetracaine (λmax = 372 nm) and pH 4 water 
(λmax = 346 nm). B) The fluorescence spectrum of tetracaine in the presence of different 
molar ratios of tetracaine: phosphate ions, where tetracaine concentration was 10 µM.   
Chapter 2: Influence of tetracaine aggregation on its passive transmembrane permeation 
 



























Figure 2.1. C) The fluorescence intensity readings at 372 nm (the fluorescence 
spectrum peak wavelength), depicting the chemical stability of tetracaine at those 
concentrations over 6 days. D) The fluorescence intensity reading at 372 nm at 5 
different temperatures.  
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An example of how aggregation data was interpreted from the fluorescence spectrum of 
tetracaine is demonstrated graphically with a 10 mm path length cuvette (Fig. 2.2.). At 
the low tetracaine concentrations, only the small Raman band of water peak was 
observed at the beginning of the spectrum (Fig. 2.2). At the medium tetracaine 
concentrations, the fluorescence emission peak increased as the concentration increased. 
Beyond 40 µM of tetracaine, the fluorescence intensity began to decrease. The plot of 
the fluorescence signal at the λmax (372 nm), shown in the last graph of Fig. 2.2, 
contained several critical points and it was these that were used to characterise the 
aggregation process of tetracaine. 
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Figure 2.2. The fluorescence spectrum of the A) low (0-10 µM) and medium (10-40 
µM) concentration ranges of tetracaine, where fluorescence intensity increases as 
concentration increases.   
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Figure 2.2. C) The fluorescence spectrum of the high (40-1000 µM) concentration 
ranges of tetracaine, where fluorescence intensity decreases as concentration increases. 
D) The re-plot of the fluorescence reading at the maximum wavelength 372 nm at 
various concentrations of tetracaine.  
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Using a 10 mm path length cuvette, high sample optical density attenuation due to 
absorption of the incident light or the emitted light can lead to a decrease in 
fluorescence intensity and a possible change in spectral distribution (Albani, 2008; 
Lakowicz, 2009). In light of the possibility of having a deviation in linearity due to the 
concentration of tetracaine and not the molecular aggregation, a path length of 3 mm 
was used to provide an off-centre illumination in order to minimise concentration-
related quenching effects (Fig. 2.3). The fluorescence data obtained from the 3 mm path 
length cuvette implied that concentration-dependent quenching did not occur at low 
tetracaine concentrations (only at 200 µM did the quenching become similar to the 10 
mm path length cuvette). Hence, for subsequent experiments, the 3 mm path length 
cuvette was used and critical points below the region of 200 µM were obtained. These 
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Figure 2.3. Graphs depicting the changes in the fluorescence intensity at λemission = 372 
nm using A) a 10 mm path length cuvette and B) a 3 mm path length cuvette. The insert 
shows an expansion of the data when a second derivative function is applied. 
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2.4.2 Tetracaine aggregation 
 
Tetracaine aggregation in the mM region was determined by photon correlation 
spectroscopy (Table 2.2). Two methods were used to interpret the data. By applying a 
second differential function to the un-attenuated derived count rate values with respect 
to tetracaine concentrations, multiple CACs were detected due to the association nature 
of tetracaine and the sensitivity of the second derivative function of the OriginPro 
programme. It appeared that the first CAC detected significantly decreased (p<0.05) 
from 40 to 0.3 mM when the pH increased from 4 to 8. Determining the CAC’s using 
the intersection method generated, a similar trend of decreasing CAC when the vehicle 
pH was increased (Fig. 2.4). The CAC significantly decreased (p<0.05) from 95.10 to 
2.91 mM when the pH increased from pH 4 to 8. 
 
Tetracaine aggregation in the µM region was monitored by fluorescence spectroscopy 
(Table 2.2). When the second derivative method was applied to the data, the first CACs 
detected significantly decreased (p<0.05) from 16 to 10 µM as pH increased from 4 to 
8. In the case where CACs were calculated using the intersection of 2 linear slopes (Fig. 
2.4), the CACs also significantly decreased  (p<0.05) from 11.06 µM in pH 4 to 7.38 
µM in pH 8. In addition, the wavelength at which maximum fluorescence intensity was 
observed experienced a significant blue shift (p<0.05) from 373 nm in pH 4 to 361 nm 
in pH 8 (Table 2.2).  
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Table 2.2. Characteristics of tetracaine aggregation in different pHs using fluorescence 
spectroscopy and photon correlation spectroscopy, where λmax represents the 
wavelength at which maximum fluorescence intensity occurs. 
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Figure 2.4. Graphs depicting critical aggregation concentrations (CACs) using photon 
correlation spectroscopy (top) and fluorescence spectroscopy (bottom) in A) pH 4. 
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Figure 2.4. Graphs depicting critical aggregation concentrations (CACs) using photon 
correlation spectroscopy (top) and fluorescence spectroscopy (bottom) in B) pH 6. 
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Figure 2.4. Graphs depicting critical aggregation concentrations (CACs) using photon 
correlation spectroscopy (top) and fluorescence spectroscopy (bottom) in C) pH 8.  
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To probe nature of the bonds formed between the aggregates in different tetracaine 
ionisation states, FTIR was employed. Based on the different CACs in different pHs 
(Table 2.2), 100 mM of tetracaine in pH 4 and 10 mM of tetracaine in pH 8 were used 
to ensure that aggregates predominantly existed in the solutions that were analysed. The 
FTIR spectrum recorded for the tetracaine solutions were presented as collected by the 
absorbance method, without deconvolution or solvent subtraction due to significant 
visible shifts in the regions of interest without further spectral manipulation (Fig. 2.5). 
The absorbance spectrum was normalised by the absorbance value at the CH3 region 
(2939 cm-1) to correct different laser intensities due to the varied concentrations used. 
As the pH increased from 4 to 8, a reduction in intensity of carbonyl group peaks (1690 
and 1606 cm-1) and secondary amide groups (1526 cm-1) was observed. An increase in 











Figure 2.5. FTIR data of tetracaine in pH 4 (filled line) and 8 (dotted line).  
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2.4.3 Tetracaine transport 
 
Two membranes were used to investigate the influence of tetracaine aggregation on its 
transport properties. The transport was studied in the silicone membrane first using a 
sequence of different tetracaine concentrations. Since each critical point recorded in the 
fluorescence spectra was referred to a change in the solution state equilibrium, it was 
suggested that at each critical concentration, a different arrangement of the molecules 
was present in the solution. In accordance with this interpretation at a tetracaine 
concentration of 16 and 50 µM, 2 different forms of aggregates of tetracaine were 
thought to be formed respectively at pH 4. Thus, the varying concentrations of 
tetracaine in the µM region were selected to try and test the tetracaine transmembrane 
transport in the presence of different aggregate forms (Table 2.2). Only the most 
interesting tetracaine donor concentrations were subsequently tested using the porcine 
membrane. 
 
In the pH 4 vehicle, the permeability coefficient through the porcine epidermis 
significantly decreased  (p<0.05) from (13.7 ± 4.3) to (0.06 ± 0.6) x 10-3 cm/h when the 
tetracaine concentration increased from 10 µM to the saturated concentration of 1.05 M. 
When the same test systems were applied to a silicone membrane, a significant decrease 
(p<0.05) from (0.7 ± 0.2) x 10-3 cm/h at 10 µM to (0.034 ± 0.005) x 10-3 cm/h at 
saturated tetracaine concentration was also observed. However, for the intermediate 
tetracaine concentrations where the types of aggregates formed were thought to change 
(Table 2.2), no effect on the permeability coefficient through the silicone membrane 
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occurred (p>0.05)(Table 2.3, Fig. 2.6 and 2.7 for permeation profiles of tetracaine 





















10 36.2 ± 11.3 13.7 ± 4.3  2.0 ± 0.6 0.7 ± 0.2 
20 - -  3.4 ± 0.7 0.7 ± 0.1 
40 - -  9.4 ± 0.7 0.8 ± 0.1 
100 - -  13.6 ± 3.3 0.5 ± 0.1 
1000 - -   177.9 ± 44.6 0.7 ± 0.2 
1.05 X 106 (1.6 ± 0.6) x 104 0.06 ± 0.02*  (9.4 ± 1.4) x 103 0.034 ± 0.005* 
 
Table 2.3. Steady state flux and permeability coefficients, kp, of different 
concentrations of tetracaine in pH 4 across porcine epidermis and silicone membrane. 
Data represent mean ± standard deviation of 3 independent tetracaine samples. * 
Significant differences were observed based on Games Howell test. 
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Figure 2.6. Permeation profiles of 10 µM and 1.05 M (◄) of tetracaine in pH 4 through 
porcine epidermis. Each point represents mean ± standard deviation (n=5).  The straight 
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Figure 2.7. Permeation profiles of 10 µM (■), 20 µM (●), 40 µM (▲), 100 µM (▼), 
1000 µM (♦) and 1.05 M (◄) of tetracaine in pH 4 through silicone membrane. Each 
point represents mean ± standard deviation (n=5). The straight lines represent the 
steady-state portion of the permeation profiles. 
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A different trend was observed when a different ionisation state of tetracaine was 
introduced in pH 8 (Table 2.4, Fig. 2.8 and 2.9 for permeation profiles of tetracaine 
through porcine epidermis and silicone membrane respectively). The permeability 
coefficient through the porcine epidermis significantly increased (p<0.05) from (29.9 ± 
9.9) to (75.1 ± 41.7) x 10-3 cm/h as the tetracaine concentration increased from 10 µM to 
the saturated concentration (6.29 mM). Using a silicone membrane, the permeability 
coefficient also significantly increased (p<0.05) from (23.5 ± 6.2) to (201.5 ± 38.2) x 
10-3 cm/h. The increase in permeability coefficient was observed in the µM region; 
when the 40 µM tetracaine donor solution was applied, a higher permeability coefficient 





















10 79.1 ± 26.1 29.9 ± 9.9  62.2 ± 16.5 23.5 ± 6.2 
40 - -  508.5 ± 56.9 48.1 ± 5.4* 
6.29 X 103 (1.2 ± 0.7) x 105 75.1 ± 41.7*  (3.4 ± 0.6) x 105 201.5 ± 38.2* 
 
Table 2.4. Steady state flux and permeability constants, kp, of different concentrations 
of tetracaine in pH 8 across porcine epidermis and silicone membrane. Data represent 
mean ± standard deviation of 3 independent tetracaine samples. * Significant differences 
were observed based on Games Howell test. 
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Figure 2.8. Permeation profiles of 10 µM (■) and 6.28 mM (▲) of tetracaine in pH 4 
through porcine epidermis. Each point represents mean ± standard deviation (n=5). The 
straight lines represent the steady-state portion of the permeation profiles. 
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Figure 2.9. Permeation profiles of 10 µM (■), 40 µM (●) and 6.28 mM (▲) of 
tetracaine in pH 4 through silicone membrane. Each point represents mean ± standard 
deviation (n=5). The straight lines represent the steady-state portion of the permeation 
profiles. 
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2.5.1 Tetracaine solution state interactions 
 
Tetracaine, also known as amethocaine, is an amphiphilic molecule, which is positively 
charged at physiological pH. The chemical structure has a hydrophilic region (amine 
portion) and a hydrophobic region (aromatic portion) and this predisposes it to self-
associate in aqueous solution. At concentrations of more than 1 mM, previous literature 
suggests tetracaine forms an aggregate (Farhadieh, Hall et al., 1967; Florence & 
Attwood, 2011; Johnson & Ludlum, 1969). There appears to be a difference of opinions 
in the literature as to whether tetracaine forms organised micelles (Kitagawa, Oda et al., 
2004; Matsuki, Ichikawa et al., 1996; Shaikh, Dagade et al., 2011) or random molecular 
aggregates (Attwood & Fletcher, 1986; Farhadieh, Hall et al., 1967). In addition, there 
is less known about at what concentration aggregation commences. 
 
There have been several studies that document tetracaine’s CAC. For example, 
Kitagawa et al. (2004) proposed tetracaine hydrochloride had a CAC of 38 mM at 25°C 
in an aqueous solution, pH ranged from 4.5 to 5.7, using an electrode method. A higher 
CAC value of 128 mM was reported based on surface tension, density and Kraft point 
measurements, at a pH of approximately 5.0 (Matsuki et al., 1994; Matsuki, Ichikawa et 
al., 1996; Miller et al., 1993). In all these previous work, relatively high drug 
concentrations were investigated and this was probably a consequence of experimental 
limitations (i.e. caused by the solvents and analytical equipment employed to detect the 
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aggregates)(Farhadieh, Hall et al., 1967; Guerin, Dumas et al., 1980; Kitagawa, Oda et 
al., 2004; Shaikh, Dagade et al., 2011; Umemura & Mantsch, 1981).  It is noteworthy 
that a high CAC value may be attributed to a high limit of detection of any given 
analytical machine. Therefore, in these cases, the CAC only represents a point where 
the aggregation equilibrium changes and a new type of structuring occurs, rather than 
the initial point of aggregation.  
 
Using photon correlation spectroscopy, the CAC results at pH 4 (40 and 200 mM) were 
close to those obtained previously (Kitagawa, Oda et al., 2004; Matsuki, Hashimoto et 
al., 1994; Matsuki, Ichikawa et al., 1996; Miller, Goodwin et al., 1993). Tetracaine 
CAC at pH 8 has not been investigated before. As the light scattering technique could 
have suffered from the same detected sensitivity problems as the previously reported 
methods of analysis, tetracaine aggregation was determined using fluorescence 
spectroscopy in addition to this technique. 
 
Fluorescence spectroscopy detects tetracaine aggregation as a consequence of the 
interactions between the monomers result in the shielding of the electrons in the 
aromatic ring to generate signal quenching. The deviation from linearity in 
concentration titration experiments can signify a change in tetracaine aggregation in the 
solution if all the other conditions that may influence this process (i.e. temperature, pH, 
ionization strength) are kept constant. In this study, the temperature and pH of the 
system were maintained. Moreover, the system was chemically stable over 6 days and 
the effect of ion pairing was not significant. The deviation from linearity in 
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concentration titration experiments signified a change in tetracaine aggregation in the 
solution as low as 16 µM in pH 4 and 10 µM in pH 8. Such low values for aggregation 
have not been previously reported.  
 
The photon correlation spectroscopy measurements helped to support the fluorescence 
measurements, even though the samples used were at two very different concentration 
ranges, because similar patterns of data were obtained from the two techniques. Both 
the photon correlation spectroscopy and fluorescence spectroscopy results show that as 
the pH increased, the CAC decreased. This phenomenon has also been shown with drug 
molecules. Attwood and Natarajan (1981) observed a higher critical micelle 
concentration at a low pH (0.5-5.5) in 5 piperazine containing drugs (trifluoperazine, 
opirpramol, thiopropazate, flupenthixol and clopenthixol). The structure of 
trifluoperazine is close to tetracaine (pKa 3.41 and 8.24); Trifluoperazine has an 
aromatic hydrocarbon and two nitrogen atoms which protonates at pKa 3.8 and 8.4. 
According to Attwood and Natarjan (1981), the increase in CMC as pH decreases is 
attributed to the increase in electrical charge of the molecule as the nitrogen atoms get 
protonated.  
 
Both fluorescence and FTIR studies seem to suggest that tetracaine ionization affects 
the type of aggregates being formed. In pH 8, the formation of tetracaine aggregates is 
accompanied by a change in the drug’s hydrophobic environment and this gave rise to 
the blue shift in λmax (Table 1). A similar trend has been observed by Mertz et al. 
(1990), who showed a fluorescence blue shift when tetracaine aggregates were 
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subjected to molecules known to form hydrogen bonds. The infrared spectra analysis of 
this work showed that the carbonyl bands intensity of tetracaine in pH 8 decrease upon 
aggregation. An investigation by Guerin et al. observed a similar decrease in carbonyl 
band intensity (1980). Tetracaine is thought to associate by stacking of the aromatic 
rings, involving mostly 𝑁 − 𝐻⋯𝑁 tertiary association with some 𝑁 − 𝐻⋯𝐶 = 𝑂 ester 
and 𝑁 − 𝐻⋯𝑁 − 𝐻  bonds and it is this process that results in the carbonyl band 
changes. 
 
In topical medicinal products, currently tetracaine is formulated at 0.15 M. Hence the 
drug probably exists as aggregates in aqueous vehicles that are presented to the skin. It 
is therefore probable that the transport of a tetracaine product is significantly influenced 
by the aggregation state of the drug. If this holds true, drug aggregation may be the 
cause of the high lag time and low penetrating amount of tetracaine (Inacio et al., In-
press).  
 
2.5.2 Tetracaine transmembrane permeation 
 
The process of passive transmembrane penetration is most commonly interpreted using 
Fick’s second law of diffusion, which is based upon the assumption that the system is 
homogeneous i.e. there are no ‘specific interactions’ between the components of the 
system (drug, vehicle and membrane)(Godin & Touitou, 2007; Kalia & Guy, 2001; 
Mitragotri et al., 2011). In an ideal scenario, i.e., one which obeys Fick’s law, the 
permeability coefficient should be constant for a drug when changing the initial loading 
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concentration of the permeating compound. Hence, any changes in permeability 
coefficient represent deviations from ideal, which can result from drug-membrane, 
drug-vehicle or drug-drug interactions. 
 
Molecular aggregation is driven by the equilibration between non-aggregates and 
aggregates in the solution state. Given its pKa, in pH 4, aggregates are most likely to be 
formed of charged tetracaine molecules. There are two hypotheses that can be generated 
to explain the decrease in the permeability coefficient of the drug when aggregates were 
formed. The first is based on the fact that only non-aggregated molecules drive 
tetracaine transport. Therefore, as the concentration of tetracaine in the solution 
increases, more aggregation occurs. Hence, there is less availability of free molecules, 
which reduces the permeability of tetracaine. Another possible hypothesis is that 
tetracaine transport is driven by both aggregates and non-aggregates. In this scenario, it 
is most likely that the charged tetracaine aggregates permeate through the skin via the 
shunt route (Edwards & Langer, 1994). The shunt route can become saturated as it is 
only present in certain regions of the skin and the aggregates may become bigger as the 
drug concentration increases. This can limit the amount of tetracaine molecules that can 
go through the appendages; hence resulting in a decrease of relative permeability of 
tetracaine. A silicone membrane is often employed in transport studies to provide a 
theoretical understanding of the simple permeation process rather than the complex 
multiple processes occurring in the heterogeneous skin, as it has no pores or availability 
of shunt routes.  As such, the similar trend from the transport of pH 4 tetracaine through 
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the silicone membrane as tetracaine aggregates were formed suggests that the former of 
the two hypotheses is more plausible. 
 
As the molecule in pH 8 forms a significant proportion of uncharged microspecies 
(28%), it is predicted that aggregates formed at this pH would be less polar than at pH 4 
(no uncharged microspecies). The less polar aggregates formed at pH 8 are more likely 
to travel through the skin via the intercellular pathway (Abraham, Chadha et al., 1995; 
Pugh et al., 1996). Just like at pH 4, the similar trend in the permeation coefficient data 
through the porcine membrane and silicone membrane suggests that aggregates do 
allow a significant amount of drug to travel through the shunt route and thus, this 
supports the fact that the non-follicular route is favoured at pH 8. There are two possible 
hypotheses to explain the increase in the permeability coefficient of tetracaine when 
aggregates were formed given that the intercellular pathway is preferred at this pH. The 
first hypothesis is an extension of the monomer penetration model (Charman, Lai et al., 
1991), which states that only non-aggregated molecules pass through the epidermis. 
Aggregates will dissociate and re-associate continually in solution and therefore, the 
number of free aggregates that are available to participate in the skin diffusion process 
is to some extent dependent upon on the aggregate kinetics. This is because as more 
monomers penetrate through the membrane, the decrease in monomer concentration in 
the donor solution will force the dynamic equilibrium between the monomers and 
aggregates in the donor solution to re-balance. If this occurs quickly, then the drug 
permeation will be higher compared to if the equilibration is slow. As tetracaine 
concentration increases, the concentration of aggregates should increase, leading to an 
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increase in the thermodynamic drive to dissociate when monomers are lost through 
adsorption through the skin. While this hypothesis seems appealing, it fails in one 
critical aspect. The time to transport tetracaine across the stratum corneum is much 
slower than the time for aggregate to dissociate (around 10-4 to 10 s)(Patist, Jha et al., 
1999). As such, the rate-determining step of tetracaine diffusion through the skin should 
be controlled by the rate of tetracaine transport through the stratum corneum, not the 
rate of aggregate dissolution. The second hypothesis is that tetracaine transport is driven 
by both aggregates and non-aggregates through the intercellular pathway (Moore, 
Puvvada et al., 2003). An increase in tetracaine concentration provides a supply of both 
monomers and aggregates, thus resulting in an increase in permeability of tetracaine.  
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In order to satisfy the aim of the thesis, a model drug that aggregates is required. In 
addition, the role of aggregation on the transport of the model drug across a membrane 
needs to be understood in order to discover if nanoparticle surface interactions can 
modify this transport process. In this chapter, tetracaine was shown to be a model drug 
that aggregates. It was shown to form aggregates in aqueous solutions in the µM range.  
In the different ionisation states, the type of aggregates formed differed in terms of 
CAC and types of bonds formed. Tetracaine aggregation changed its drug permeation 
process. At pH 4, aggregates decreased tetracaine permeability coefficient but at pH 8, 
aggregates had the opposite effect. Thus, it seems plausible that nanoparticles could 
modify aggregation in the design of a strategy to enhance tetracaine permeation through 
the skin – a concept that will be investigated with the application of nanomaterials in 
Chapter 3.  
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In the previous chapter, drug aggregation was shown to be able to influence the ability 
of a molecule to move through a membrane passively. Drug aggregates can arise from 
drug-drug interactions or drug-excipient interactions. In either case, the molecules that 
form aggregates exhibit different physicochemical properties in solution compared to 
non-aggregated molecules and this is one of the main reasons why the permeation 
properties through a membrane are modified. Knowledge of this phenomenon provides 
a basis to suggest that controlling the aggregation process can be used as a strategy to 
enhance drug percutaneous penetration. The control of drug aggregation could be 
achieved by the addition of substances that interact with a drug and thus, compete with 
the molecule’s ability to self-associate. However, such a strategy has not been used to 
deliberately improve the topical penetration of topical agents into the skin to date.  
 
Studies that investigated the interactions in pharmaceutical formulations have shown 
that the addition of electrolytes (Attwood & Udeala, 1975), surfactants and polymers 
(Pygall, Griffiths et al., 2011) can disrupt drug molecular aggregation by interacting 
with the molecule that is self-associating. For example, simple surfactants have been 
used to break up the aggregation of small molecular weight agents such as 
phthalocyanines and larger therapeutic agents such as insulin (Darwent, McCubbin et 
al., 1982; Rossetti, Lopes et al., 2011; Shao, Li et al., 1993; Spikes & Bommer, 1986). 
Surface-active solid nanomaterials could be used to facilitate drug-drug aggregation and 
thus, may modify the subsequent drug penetration through a membrane. However, the 
Chapter 3: Harnessing the unique surface properties of nanomaterials to improve drug 





X. J. Cai 
88 
link between drug aggregation, nanomaterial surface effects and transmembrane 
transport needs further study.  
 
A myriad of nanomaterials have been used in pharmaceutical and cosmetic formulations 
– lipids, polymers, metals, minerals etc. (Muller et al., 2002; Prow, Grice et al., 2011) 
(reviewed in Section 1.5). The body of literature that has been generated during the 
development of these systems has suggested that nanomaterials can be used to mask 
colour and odour (Kuelkamp-Guerreiro, Berlitz et al., 2013; Souto, Muller et al., 2005), 
control release of drugs across the membrane (Jenning et al., 2000; Puglia et al., 2008) 
and provide chemical protection by loading inside a particle (Dingler et al., 1999; 
Trombino, Cassano et al., 2009). One of the most exciting attributes of nanoparticles is 
that they have also shown to enhance drug transport across the skin (Alves et al., 2007; 
Borgia et al., 2005; Chen et al., 2006).  
 
The introduction of nanomaterials into a topical product applied to the skin does not 
always guarantee drug percutaneous enhancement. This is especially the case if the 
materials are used as drug carriers, i.e., the drug is loaded within the nanoparticle. These 
nanocarriers can add a second rate-limiting step to the drug penetration process (Baroli, 
2010a) and they pose additional challenges when they have low loading capacity 
(Schäfer-Korting, Mehnert et al., 2007), premature drug release (Zhao, Brown et al., 
2010) and poor drug release (Muller & Kreuter, 1999). These issues can to some extent 
be circumvented if rather than being employed as a drug carrier nanomaterials, are 
employed to control drug aggregation through their surface interactions.  
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As such, the aim of this chapter was to study the influence of nanomaterials on 
transmembrane transport when co-administered to the skin. It was hypothesized that 
nanomaterials could be used to perturb drug aggregation in the way that promotes drug 
permeation and it was hoped that such a penetration enhancing strategy could be applied 
to the topical delivery of amphiphilic drugs. Negatively charged carboxyl-modified 
polystyrene nanoparticles and silica nanoparticles were used to represent two different 
nanomaterial surfaces and their properties were characterised using light scattering and 
atomic force microscopy (AFM). The addition of simple counter-ions to the drug in 
solution was used to investigate if the drug would respond to binding to the nanoparticle 
surface in a similar manner. In addition, the effect of the nanoparticles equilibrating 
with the drug in solution was investigated. Two barriers, the porcine epidermis and a 
silicone membrane, were used in the studies in order to understand the delivery of the 
drug through a barrier with and without the follicular transport route. The follicular 
transport route has previously been shown to be important when nanomaterials are 
presented to the barrier topically (Knorr, Lademann et al., 2009).  
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Material Specifications Company 
Tetracaine  
 
Free base, ≥ 98% Sigma Aldrich, UK Nano!"#$$% Carboxyl-modified polystyrene 
nanoparticles with a diameter of 
60 nm (PC02N) 
 
2B Scientific, UK 
Nano!"#! Silica nanoparticles with a 
diameter of 200 nm (Psi-0.2) 
Kisker Biotech 
GmbH and Co., 
Germany 
 
Hydrochloric acid (HCl) 
 
Fuming, 37% Sigma Aldrich, UK 
Phosphate buffered saline 
  
Tablets, pH 7.4, 0.172 M Oxoid Ltd, UK 
De-ionised water 
 
Electrical conductivity 0.5-1 µS Produced in house 
Poly-L-lysine solution 
 
0.1% w/v Sigma Aldrich, UK 
Ethanol 
 
200 Proof, ACS Reagent Sigma Aldrich, UK 




Cantilevers Uncoated Si3N4 cantilevers with 
integrated pyramidal tips 






Anhydrous, ≥ 99.5% Sigma Aldrich, UK 
 
Centrifugal filters Amicon Ultra 0.5 mL, Nominal 







Anhydrous, ≥ 99% Sigma Aldrich, UK 
Acetic acid 
 
ACS reagent, ≥ 99.7% Sigma Aldrich, UK 
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Acetonitrile High performance liquid 
chromatography (HPLC) grade 
 
Fisher Scientific, UK 
Methanol 
 
HPLC grade Fisher Scientific, UK 
Water 
 
HPLC grade Fisher Scientific, UK 
Silicone membrane  Thickness of 0.12 mm GBUK Healthcare, 
UK 
 
Table 3.1. Materials used in Chapter 3.  
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3.3.1 Test sample preparation 
 
Tetracaine solutions were prepared and adjusted to pH 4.0 and 8.0 using HCl and 
equilibrated at 32°C unless stated otherwise. Solutions were stirred for at least 24 h and 
their pH was rechecked prior to analysis to ensure they were at equilibrium. The vehicle 
containing the nanoparticles was corrected to the necessary pH using HCl prior to 
mixing with tetracaine solutions. 
 
3.3.2 Atomic force microscopy (AFM) imaging 
 
The AFM images were obtained using a Nanoscope V Dimension Icon atomic force 
microscope (Bruker, US).  Uncoated Si3N4 cantilevers with integrated pyramidal tips 
with a reported high resonance frequency of 325 kHz and high spring constant of 46 
N/m was used for the tapping mode AFM imaging in air. The Nano!"#$$%  and Nano!"#! images were taken after deposition on freshly cleaved mica surfaces. To 
facilitate nanoparticle deposition, an aqueous 0.1% (w/v) poly-L-lysine solution was 
applied to mica prior to the addition of the nanoparticles, After acquisition, the images 
were flattened and analysed using section analysis with Gwyddion version 2.36, a free 
SPM data visualization and analysis programme.  
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3.3.3 Photon correlation spectroscopy  
 
The nanoparticle size was analysed by photon correlation spectroscopy (PCS)(Malvern 
Nanoseries Zetasizer ZEN3600, Malvern Instruments Ltd, UK). Detection of the light 
scattering signal was achieved at a 173° backscattering angle with samples equilibrated 
at 32°C using water as a dispersant (refractive index 1.33, viscosity 0.8872 cP). Each 
measurement comprised of 10-14 runs. The zeta potential of the nanoparticles was 
recorded using the same Malvern Nanoseries Zetasizer instrument using zeta potential 
capillary cells. Prior to the zeta potential measurements, the samples were prepared in 
10 mM sodium chloride (NaCl) to normalise the sample osmolality. The measured 
electrophoretic mobility was converted into zeta potential using Smoluchowski’s 
formula. Each measurement comprised of 50 to 100 runs. Triplicates of each sample 
were assessed. In an attempt to estimate the pKa at the nanoparticle surfaces and 
determine the isoelectric point a zeta potential titration was performed by measuring the 
zeta potential of the particles at pH units between pH 1 to 11. The pH of the solution 
was adjusted using HCl. A logarithm curve was fitted onto the zeta potential titration 
cure using the OriginPro software (OriginPro version 8.6, OriginLab Corporation, US) 
to calculate the isoelectric point and the pKa. 
 
3.3.4 Tetracaine transport studies 
 
Infinite dose permeation experiments were conducted as described previously in Section 
2.3.6. However, in this chapter a 0.5 mL aliquot of the nanoparticle suspension was 
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added to 0.5 mL of 20 µM of the tetracaine solution at the 0 h time point after 
correcting the suspension medium pH to 4 or 8. The final tetracaine concentration in the 
nanoparticle-tetracaine mixtures was 10 µM. HPLC grade water was added in place of 
the additives in the control system. The direct mixing of the drug and nanoparticles on 
the surface of the skin was the preferred application method throughout the study as it 
minimised any potential interference from chemical or physical instability as a 
consequence of forming the mixture. A concentration of 0.001 g/mL of Nano!"#$$% 
and 6.289 g/mL of Nano!"#!, which provided an equivalent surface area to volume ratio 
of 9.43x10-10:1 µm2/mL, were added to 10 µM tetracaine solutions to investigate the 
effects of nanomaterials on tetracaine transport.  
 
As a control experiment, the influence of electrolytes on tetracaine transport was 
determined by subjecting tetracaine to an environment of phosphate ions. At pH 4, the 
electrolyte used in this study, anhydrous sodium dihydrogen phosphate (which has 3 
pKa at 1.85, 6.89 and 12.70) dissociates to form predominantly the monovalent 
dihyrogen phosphate ions (H2PO4-). To investigate the effects of pre-equilibration of 
tetracaine-nanoparticles mixtures, the tetracaine solutions were mixed with the 
nanoparticles for 30 days before application. The vehicle of the nanoparticles, used in 
the transport studies to test if there was any penetration effect of the solution alone, was 
obtained by using a centrifugal filter with nominal molecular weight limit of 100 kDa at 
1500 g for 10 min (Biofuge pico, Heraeus Instruments, Germany). 
 
The determination of the steady state flux (J) was achieved as per the method described 
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previously in Section 2.3.6 and the enhancement ratios (ER) due to the various additives 
were determined using the following equation:  
 ER =    !!!!                                           (Equation 3.1) 
 
where J1 and J2 are the steady state transmembrane transport rate of tetracaine from the 
tetracaine and tetracaine-nanoparticle mixture respectively. 
 
3.3.5 Tetracaine quantification 
 
Refer to Section 2.3.7. 
 
3.3.6 Statistical analysis 
 
Refer to Section 2.3.8. 
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3.4.1 Particle characterisation  
 
The carboxyl-modified polystyrene nanoparticles ( Nano!"#$$% ) and silica 
nanoparticles (  Nano!"#! ) showed properties in accordance with the manufacturers 
specification (Table 3.2). 
 
Tip-substrate Nano!"#!!" Nano!"#! 
Diameter according to the 
manufacturer’s data (nm) 
 
60.0 200 
Mean diameter PCS (nm) 
 
56.9 ± 0.7 246.6 ± 2.6 
Mean diameter AFM (nm) 
 
36.8 ± 7.3 197 ± 6.6 




Surface functional groups 
 
-COOH, -SO4 -OH 
pKa 
 




Zeta potential at pH 4 (mV) 
 
- 40.3 ± 1.2 - 22.7 ± 1.4 
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In this study, the size and zeta potential of the nanoparticles when subjected to 10 µM 
tetracaine concentration remained largely unchanged (Table 3.3). 
 
  
Diameter using PCS (nm) Zeta potential (mV) 
Nano!"#$$% Nano!"#! Nano!"#$$% Nano!"#! 
 
pH 4 water 
 
 
56.9 ± 0.7 
 
242.6 ± 2.6 
 
-40.3 ± 1.2 
 
 
-22.7 ± 1.4 
10 µM of tetracaine 57.0 ± 0.6 239.6 ± 0.9 -39.0 ± 0.9 -24.0 ± 0.7 
 
Table. 3.3. Diameters of carboxyl-modified polystyrene nanoparticles, Nano!"#$$%, 
and silica nanoparticles Nano!"#!.  
 
The mean diameter of the Nano!"#$$% obtained from the cross-sectional analysis of 
AFM (36.8 ± 7.3 nm)(Fig. 3.1) was significantly smaller (independent t-test, p<0.05) 
than those obtained using photon correlation spectroscopy (56.9 ± 0.7 nm)(Table 3.2). 
The manufacture of the Nano!"#$$% was such that they would most probably have both 
carboxyl and sulphated groups present on their surface. The pKa values for the particles 
were not available and they could not be measured by simple zeta potential methods 
applied (Fig. 3.3), but the particle functional groups were expected to be fully ionised 
between pH 5-9 based on the reference pKa values for carboxyl and sulphate groups 
(Manufacturer’s data).  
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The mean diameter of the Nano!"#! obtained from the cross-sectional analysis of AFM 
(Fig. 3.2) was significantly smaller (independent t-test, p<0.05) to those obtained using 
photon correlation spectroscopy (242.6 ± 2.6 nm)(Table 3.2). Silica nanoparticles in an 
aqueous environment are known to have hydroxyl surface groups (Zhuravlev, 2000). 
The zeta potential data for the Nano!"#! suggested they had a pKa of 4.03 and an 
isoelectric point of 2.00 (Fig. 3.3). In an aqueous solution set at pH 4, the surface charge 
of the Nano!"#!  was significantly less negative (independent t-test, p<0.05) than Nano!"#$$% and this data inferred that the pKa for the carboxyl-modified particles was 
actually a little higher than 4. 
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Figure 3.1. Tapping mode AFM topography image of carboxyl-modified polystyrene 
nanoparticles, Nano!"#$$% , (A) and the cross-sectional profiles of 3 selected 
nanoparticles (B).  
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Figure 3.2. Tapping mode AFM topography image of silica nanoparticles Nano!"#!, 
(A) and the cross-sectional profiles of 3 selected nanoparticles (B).  
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Figure 3.3. Surface charge distribution of carboxyl-modified polystyrene nanoparticles Nano!"#$$% (A), and silica nanoparticles Nano!"#! (B). 
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3.4.2 Effect of nanomaterials on tetracaine transport 
 
There was no significant difference between the fluxes through the skin when the 
tetracaine was added directly to the skin or if it was diluted on the surface of the skin to 
the same concentration (Table 3.4). This test was performed to validate the effects of 
mixing the formulations on the skin in subsequent experiments.  
 
Donor solution  Flux (ng/cm2/h) 
1 mL of 10 µM tetracaine 2.0 ± 0.4 
0.5 mL of 20 µM tetracaine + 0.5 mL of water 2.0 ± 0.6 
 
 
Table. 3.4. Steady state flux of tetracaine through silicone membrane with a final 
concentration of 10 µM prepared by 2 different procedures. 
 
Tetracaine transport was modified when the negative surfaces (Nano!"#$$%  and Nano!"#!) were added to the tetracaine solution at both pH 4 and 8 (Table 3.5). 
 
   
Concentration (mM) 
Porcine epidermis  







   10 µM TET 36.2 ± 11.3 13.7 ± 4.3 -  
10 µM TET + Nano!"#$$% 0 0 - * 
10 µM TET + Nano!"#! 122.5 ± 31.0 42.3 ± 11.7 3.6 ± 1.2* 
pH
 8
   10 µM TET 79.1 ± 26.1 29.9 ± 9.9 - 
 10 µM TET + Nano!"#$$% 0 0 - * 
 10 µM TET + Nano!"#! 148.1 ± 23.9 56.0 ± 8.9 2.0 ± 0.5* 
 
 
Table 3.5.  Steady state flux and permeability constants, kp, and enhancement ratio of 
10 µM of tetracaine in the presence of different additives in pH 4 and 8 across porcine 
epidermis. Data represent mean ± standard deviation of 3 independent tetracaine 
samples. * Significant differences were observed based on Dunnett’s test. 
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At pH 4, the Nano!"#$$% significantly (p<0.05) hindered the percutaneous permeation 
of tetracaine through the porcine skin, reducing the drug flux from 36.2 ± 11.3 ng/cm2/h 
to undetectable levels. When the same test systems were applied at pH 8, the addition of Nano!"#$$% to the tetracaine solutions showed similar adverse effect on tetracaine 
transport across the porcine epidermis (Table 3.5, Fig. 3.4 for permeation graphs). 
 
At pH 4, the Nano!"#!    significantly enhanced (p<0.05) percutaneous tetracaine 
transport by 3.6-fold. At pH 8, the Nano!"#! increased the transport rate across the 
porcine skin by 2.0-fold (Table 3.5, Fig. 3.4 for permeation graphs). 
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Figure 3.4. Permeation profiles of 10 µM of tetracaine (■) with the addition of 
carboxyl-modified polystyrene nanoparticles, Nano!"#$$% (▲) and unmodified silica 
nanoparticles, Nano!"#!(●) in pH 4 (A) and pH 8 (B) across porcine epidermis. Each 
point represents the mean ± standard deviation, n=5. The straight lines represent the 
steady-state portion of the permeation profiles. 
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The silicone membrane was used to attempt to understand the penetration enhancement 
observed through the porcine skin when the nanoparticles were mixed with the 
tetracaine (Table 3.6). These studies demonstrated that the simple addition of phosphate 
ions did not have a membrane penetration enhancement effect on tetracaine (1.7 ± 0.2 








10 µM TET 2.0 ± 0.4 0.8 ± 0.2 - 
10 µM TET + phosphate ions 1.7 ± 0.2 0.6 ± 0.1 0.9 ± 0.2 
10 µM TET + Nano!"#$$% 0 0 - * 
10 µM TET + Nano!"#$$%  (equilibrated) 0 0 -* 
10 µM TET + Nano!"#$$% vehicle 1.9 ± 0.6 0.7 ± 0.2 1.0 ± 0.3 
10 µM TET + Nano!"#! 213.6 ± 40.4 80.8 ± 15.1 111.9 ± 38.5* 
10 µM TET + Nano!"#! (equilibrated) 273.3 ± 37.6 103.4 ± 14.2 140.6 ± 35.4* 
10 µM TET + Nano!"#!  vehicle 48.6 ± 4.4 18.4 ± 1.7 24.7 ± 3.5* 
 
 
Table 3.6. The effects of nanomaterial on the steady state flux, permeability coefficient 
(kp) and enhancement ratio of 10 µM of tetracaine at pH 4 and 8 across silicone 
membrane. Data represent mean ± standard deviation of 3 independent tetracaine 
samples. * Significant differences were observed based on independent  
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The pre-equilibrated Nano!"#$$%-tetracaine mixtures prior to application to the silicone 
membrane significantly reduced (p<0.05) tetracaine transport across the hydrophobic 
barrier to undetectable levels. Similar were obtained when the nanoparticles were co-
administered directly in the donor compartment of the Franz diffusion cells prior to the 
start of the transport experiments and when they were pre-equilibrated for 30 days prior 
to addition to the membrane (Table 3.6, Fig. 3.5 for permeation profiles). The silicone 
membrane penetration studies also demonstrated that the vehicle isolated from the Nano!"#$$% , which consists of 0.05% NaN3 and 0.1% SDS according to 
manufacturer’s data, did not play a role in enhancing tetracaine transport (p>0.05, Table 





















Figure 3.5. Permeation profiles of 10 µM of tetracaine (■) with the addition of 
carboxyl-modified polystyrene nanoparticles, Nano!"#$$% nanomaterials (▲), 
investigating the effects of 30-day equilibration (equilibrated, ●) and the vehicle of the Nano!"#$$%  (▼). Each point represents the mean ± standard deviation, n=5. The 
straight lines represent the steady-state portion of the permeation profiles. 
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In the Nano!"#!-tetracaine mixtures, the incubated Nano!"#!-tetracaine mixture and the Nano!"#!mixture mixed on the surface of the membrane both significantly enhanced 
transport; there was only a very small, but statistically significant difference (p<0.05) 
between the two (Table 3.6, Fig. 3.6 for permeation profiles). Unlike the Nano!"#$$%, 
the vehicle isolated from the Nano!"#! suspension played a comparatively small, but 
significant role (p<0.05) in the penetration enhancement of tetracaine through a 
membrane – transport was significantly increased by approximately 25-fold (Table 3.6, 
Fig. 3.6 for permeation profiles). Based on the manufacturer’s data, the Nano!"#! 
consisted only of amorphous silica in water. Hence, the major constituent in the 
aqueous vehicle that suspended the nanoparticles was soluble silica.  
 
 
Figure 3.6. Permeation profiles of 10 µM of tetracaine (■) with the addition of 
phosphate ions (♦) and silica nanoparticles, Nano!"#!nanomaterials (▲), investigating 
the effects of 30-day equilibration (equilibrated, ●) and the vehicle of the Nano!"#! 
(▼). Each point represents the mean ± standard deviation, n=5. The straight lines 
represent the steady-state portion of the permeation profiles.  
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The ability of nanomaterials to enhance drug transport across hydrophobic membranes 
has been previously reported in the literature and this effect as replicated in the data 
reported in this study (Alves et al., 2007; Borgia et al., 2005; Chen et al., 2006). What 
was particular about the current work is that the transport was assessed upon the 
dynamic mixing of a solid nanoparticle and a drug, i.e., the drug was not loaded into the 
nanoparticles. Therefore, the enhanced transport was a direct consequence of the surface 
interactions of the solid substrate and the drug molecules in solution. The addition of 
equivalent drug to surface area ratios of Nano!"#$$% and Nano!"#! to the Franz cell 
experiments resulted in very different tetracaine transport profiles. 
 
In Chapter 2, the model drug tetracaine was shown to aggregate in aqueous solutions 
and that this process influenced percutaneous penetration. It was anticipated that 
nanoparticle surface interactions would modify the transport of a drug across a 
membrane by modifying this aggregation process. This idea was based on the prior 
reports that drug-drug interactions can be modified by the addition of substances that 
compete for association sites (Florence & Attwood, 2011). Theoretically, electrolytes, 
surfactants, polymers and solid interfaces can disrupt drug-drug interactions via 
competitive interaction. However, in this study, the addition of dihydrogen phosphate 
electrolytes had no effect on the transport rates of tetracaine (1:10000 tetracaine to 
phosphate ratio). This suggested that the tetracaine-tetracaine aggregation could not be 
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disrupted by the relatively weak ion-pair interactions that are formed between the 
phosphate and the drug. 
 
Nanoparticles were used to introduce a solid interface into the mixture and this was 
shown to perturb tetracaine aggregation. However, this interaction did not induce a 
change in the size and zeta potential of the nanoparticles when subjected to 10 µM 
tetracaine concentration remained largely unchanged. This was contrary to the results 
obtained by Mocanu et al. (2012), who observed a decrease in zeta potential values and 
suggested the presence of electrostatic attractions between the nanoparticles and the 
tetracaine molecules. The difference in the results obtained in the current work was 
probably due to the different concentrations investigated. In this study, 10 µM of 
tetracaine was used, but in the previous work a concentration of more than 100 mM was 
used. A low concentration of tetracaine was used in the current study to increase the 
potential for nanoparticle surface interactions to have an influence on percutaneous 
penetration. 
 
3.5.1 The introduction of 𝐍𝐚𝐧𝐨𝐏𝐒𝐂𝐎𝐎𝐇 
 
In pharmaceutical products applied to the skin, polymers can be used as thickening 
agents and drug carriers (Alvarez-Román et al., 2001; Lboutounne et al., 2002; Luengo 
et al., 2006). However, in this study, negatively charged polystyrene nanoparticles were 
used to provide a solid interface in the hope that drug-drug association would be broken 
to enhance drug transport across the skin.  
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When tetracaine was mixed with Nano!"#$$% , the particles prevented the drug’s 
penetration through both the porcine and silicone barriers. Tetracaine was unable to 
penetrate through the membranes when the Nano!"#$$% were mixed with the drug 
directly on the surface of the skin and when they were pre-equilibrated with the drug. 
Thus, it appeared that the pre-equlibration of the drug and the nanoparticles had little 
effect on this nanoparticle drug mixture. The vehicle of Nano!"#$$%, which constituted 
of SDS, did not significantly influenced tetracaine transport. As such, any modification 
to the tetracaine transport was assigned to interactions with the surface of Nano!"#$$%. 
 
3.5.2 The introduction of 𝐍𝐚𝐧𝐨𝐒𝐢𝐎𝟐 
 
Silica nanoparticles are one of the four most used nanomaterial in terms of commercial 
production, together with titanium oxide, zinc oxide and silver nanoparticles. They are 
widely applied in the fields of pharmaceutical and cosmetic products (Lövestam et al., 
2010). In terms of topical formulations, silica nanoparticles are often used as a viscosity 
modifier or suspending agent in gels, microemulsions and semi-solid preparations 
(Napierska et al., 2010). They are also used as an emulsion stabilizer to form Pickering 
emulsions due to their surface activity (Frelichowska, Bolzinger, Pelletier et al., 2009; 
Frelichowska, Bolzinger, Valour et al., 2009) and have been shown to modulate drug 
diffusion from the topical emulsions. For example, Frelichowska et al. (2009) 
demonstrated that Pickering emulsions (silica particle-stabilised w/o emulsions) 
exhibited 3-fold higher caffeine flux than conventional emulsions (surfactant-stabilised 
w/o emulsions. 
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However, using the nanoparticles as a physical surface to modify the aggregation state 
of a drug to enhance transmembrane transport does not seem to have been previously 
been reported. The Nano!"#!-tetracaine system that was incubated together for 30 days 
and the Nano!"#!-tetracaine system that was mixed on the surface of the skin both gave 
impressive enhancement effects when measuring transport across the silicone 
membrane. The tetracaine transport results from the vehicle of the nanoparticle 
suggested that soluble silica available in the aqueous phase of the Nano!"#! suspension 
played a role in enhancing tetracaine transport even though these effects were 
comparably small compared to when the particles were also present in the system. The 
higher permeability when Nano!"#! were added to the drug seems to suggest that the Nano!"#!-tetracaine interactions modified the tetracaine through barriers. The fact that 
this enhancement was greater in the silicone membrane rather than the skin is most 
probably due to known tetracaine binding to the keratin in the skin which could 
diminish the enhancement.  
 
The difference in enhancement ratios when Nano!"#! were added to tetracaine at 
different pHs supported the hypothesis that tetracaine permeation can be enhanced by 
the modification of drug aggregation. At pH 4, the tetracaine aggregates do not 
permeate through the membrane (Chapter 2) and the addition of Nano!!"! may break up 
the non-permeating aggregates in a manner that could facilitate the temporal increase in 
drug monomers that could permeate across the skin. At pH 8, both the non-aggregated 
and aggregated tetracaine drove the drug transport (Chapter 2) and the break down of 
tetracaine aggregates when Nano!"#!  were added resulted in an increase in drug 
permeation, but not one that is as high as at pH 4.   
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The co-administration of  Nano!"#!with tetracaine in a simple aqueous formulation 
enhanced percutaneous drug penetration when applied topically. This finding suggests 
that some topical preparations could be improved simply by the addition of 
nanoparticles, i.e., there may be no need, in certain circumstances, to encapsulate the 
drug within the nanoparticle to gain a beneficial effect. However, the data suggested the 
type of nanoparticles was important as Nano!"#$$%  hindered the tetracaine 
percutaneous penetration. This difference in tetracaine transport profiles suggest that the 
drug-nanomaterial interactions drove the differences in the transport profile and to 
understand this further, these interactions were carefully investigated in Chapter 4. 
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Nanomaterials may be used as drug carriers and penetrate into the stratum corneum as 
intact vesicles before releasing their contents in the skin. However, this mechanism is 
limited to elastic vesicles such as ethosomes and transfersomes, which have generated 
some evidence that they can enter the deeper layers of the stratum corneum 
(Honeywell-Nguyen et al., 2004). Rigid nanomaterials with a size of greater than 20 
nm, the focus of this study, generally do not penetrate the skin to a great extent (Baroli 
et al., 2007; Ryman-Rasmussen et al., 2006; Wu, Price et al., 2009).  Therefore, these 
types of nanoparticles must release their loaded drug at or near the skin surface so that it 
can subsequently penetrate into the tissue. When this occurs, enhancement of drug 
transport into the skin have been suggested to be a consequence of generating a drug 
reservoir on the skin surface (Alvarez-Roman et al., 2004a; Lademann et al., 2007), 
modifying the skin barrier (Peira et al., 2014; Schlupp et al., 2011), providing occlusion 
(Dingler et al., 1999; Pardeike et al., 2009), changing the physicochemical properties of 
the drug to increase the diffusivity in the skin (Luengo et al., 2006), changing the 
partition coefficient of the drug to increase its release from the formulation (Rouzes et 
al., 2003) or increasing the thermodynamic activity of the drug in the vehicle and the 
skin (Alvarez-Roman, Naik, Kalia et al., 2004c; Fangueiro et al., 2012).   
 
One alternative suggestion of how nanomaterials could enhance topical drug delivery is 
through the surface interactions of the particulate with the drug. This is especially 
important if the therapeutic agent applied to the skin has a tendency to aggregate. For 
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surface-active drugs, the drug-nanoparticle surface interactions are probably more 
important than the other potential penetration enhancing effects aforementioned because 
drug-nanoparticle surface interactions may alter the drug-drug interaction equilibrium, 
similar to surfactants (Darwent, McCubbin et al., 1982; Rossetti, Lopes et al., 2011; 
Shao, Li et al., 1993; Spikes & Bommer, 1986) and polymers (Pygall, Griffiths et al., 
2011). As shown in Chapter 2, the manner in which amphiphilic molecules, such as 
tetracaine, presents itself in the solution can influence the drug percutaneous 
penetration. The perturbation of drug-drug interactions by drug-nanoparticle surface 
interactions has the potential to change the self-diffusion coefficient of the drug in the 
application vehicle and thus, the rate of entry into the skin barrier. Nanomaterials were 
shown in Chapter 3 to enhance drug percutaneous penetration by 3.6-fold at pH 4 and 
2.0-fold at pH 8. Although it was hypothesised that the enhancement in percutaneous 
penetration was brought about by nanoparticle surface interactions with the drug, just 
like previous studies, no direct spectroscopic evidence was generated to support this 
notion (Schlupp, Blaschke et al., 2011). 
 
The aim of this chapter was to examine if the interactions that occurred between the 
nanoparticulate surface and the drug used in Chapter 3 conferred the capability to 
enhance percutaneous penetration. As the main aim of the PhD was to develop a 
nanomaterial formulation that enhanced drug transport, it was anticipated that 
understanding the mechanism of achieving an enhancement would enable us to further 
optimize this system in subsequent chapters of the thesis. To detect the presence of 
nanomaterials-drug aggregate interactions in the aqueous solutions, physical adsorption 
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and fluorescence spectroscopic studies were conducted. In order to acquire detailed 
knowledge of the magnitude of these tetracaine-nanoparticle interactions, AFM was 
utilized. Methyl and an ionized tertiary amide functionalized tips were generated in the 
work in order to mimic the two ends of the charged tetracaine molecule. Adhesion 
forces between the tetracaine molecule via these two functional representatives of 
tetracaine and the different nanomaterials were then measured. 
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4.2 Materials 	  




Free base, ≥ 98% Sigma Aldrich, UK Nano!"#$$% Carboxyl-modified polystyrene 
nanoparticles with a diameter of 20 
µm (PC07N) 
 
2B Scientific, UK 
Nano!"#! Silica nanoparticles with a diameter 
of 20 µm (Psi-20.0) 
 
Kisker Biotech GmbH and 
Co., Germany 
Hydrochloric acid (HCl) 
 
Fuming 37% Sigma Aldrich, UK 
De-ionised water Electrical conductivity 0.5-1 µS 
 
Produced in house 
Centrifugal filters Amicon Ultra 0.5 mL, Nominal 
molecular weight limit of 100 kDa 
 
Millipore Limited, UK 
Sodium acetate 
 
Anhydrous, ≥ 99.9% Sigma Adrich, UK 
Acetic acid 
 
ACS reagent, ≥ 99.7% Sigma Aldrich, UK 
Acetonitrile, methanol and 
water 
 
High performance liquid 
chromatography (HPLC) grade 
Fisher Scientific, UK 
Methanol 
 
HPLC grade Fisher Scientific, UK 
Poly-L-lysine solution 
 
0.1% w/v Sigma Aldrich, UK 
1-octadecanethiol 
 





- Sigma Aldrich, UK 
Ethanol 
 




Mica surfaces - Agar Scientific, Elektron 
Technology UK Limited 
 
Cantilevers  Gold-coated Si3N4 V-shaped 
contact mode cantilevers with 





Table 4.1. Materials used in Chapter 4.  
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4.3.1 Test sample preparation 
 
Refer to Section 3.3.1. 
 
4.3.2 Physical adsorption 
 
Nanoparticles were added to tetracaine solutions at time point 0 h and at several 
subsequent time points (0.25, 0.50. 0.75, 1, 3, 5, 24 and 48 h). 500 µL of the tetracaine-
nanoparticle mixtures were removed and centrifuged through a centrifugal filter with 
nominal molecular weight limit of 100 kDa at 1500 g for 10 min (Biofuge pico, Heraeus 
Instruments, Germany). A 300 µL aliquot of the centrifuged liquid phase was 
transferred into vials. The analyte was dissolved in a 1:2 ratio v/v with acetonitrile and 
unbound tetracaine concentrations were determined using the HPLC assay. Tetracaine-
nanoparticle binding was calculated using equation 4.1: 
 C! % =    !!!! X  100  %                                   (Equation 4.1) 
 
where  C! is the concentration of the bound tetracaine, C! is the unbound tetracaine 
analysed at the time point and C!  is the initial tetracaine.  
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4.3.3 Fluorescence spectroscopy 
 
Refer to Section 2.3.3. 
 
Any background signal generated by the nanoparticles was subtracted from the 
measurements to focus the results on the tetracaine fluorescence. 
 
4.3.4 Atomic force microscopy (AFM) 
 
Refer to Section 3.3.2 for the AFM imaging procedure. 
 
The force adhesion measurements between the functionalized tips and functionalized 
substrates were obtained using a Nanoscope V Dimension Icon atomic force microscope 
(Bruker, US). To mimic the conditions in the Franz cell experiments, the substrates 
were analysed using a fluid cell housed in a petri dish. The fluid cell was washed with 
detergent water and rinsed with ultrapure water before drying with a steam of nitrogen 
gas prior to the start of every experiment. The same individual AFM tip was used in all 
experiments in order to cancel out possible variations caused by different tip properties 
such as tip size, etc. 
 
The functionalized materials employed in the force adhesion AFM measurements were 
produced using a gold-thiol coating procedure. 1-octadecanethiol and (11-
Mercaptoundecyl)-N,N-N-trimethylammonium bromide were selected as the thiols 
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because they produced functional groups on the surface of the materials which best 
mimicked the two terminuses of the tetracaine molecule. The material functionalisation 
was achieved by incubating the gold-coated AFM materials (i.e., AFM substrates and 
AFM cantilevers) in freshly prepared 3 mM solution of the chosen thiol, which was 
dissolved in ethanol overnight in a sealed petri dish. After incubation, the substrates and 
AFM probes were washed thoroughly with ethanol. The substrates were dried with 
nitrogen while the AFM probes were allowed to dry in air.  
 
Particles were deposited on the surface of mica substrates as described in Section 3.3.2. 
Microparticles of 20 µm in diameter from the same manufacturer and particle series 
were used in place of the nanoparticles to provide a wider contact surface for the AFM 
tip.  
 
Prior to making the force-adhesion measurements, the spring constant of the cantilevers 
was determined. The photodetector sensitivity was first calibrated by determining the 
slope of the repulsive branch of a force curve on a hard surface (photodetector signal 
versus z-scanner displacement plot on mica). Then, thermal tuning was performed using 
the corresponding Nanoscope programme function to determine the actual spring 
constants of the cantilevers. Gold-coated Si3N4 V-shaped contact mode cantilevers with 
integrated pyramidal tips (Model: NPG10) were used to obtain the force measurements. 
The nominal spring constant specified in the cantilever datasheets was 0.35 N/m and the 
measured spring constants were (0.39 ± 0.01) N/m. Three independent measurements of 
210 force curves were obtained from 10 randomly distributed areas on the sample 
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surfaces to ensure representative sampling. Average adhesion force values were 
determined by fitting a Gaussian profile to the histogram of the forces using OriginPro 
software.  
 
Sessile drop contact angles were captured by a high resolution camera (Photron Ultima 
APX Monochrome, UK) and analysed using Image J with a Dropsnake plug-in to 
confirm the formation of surface modified gold substrate. In addition, force interactions 
between the tip and CH3 substrates were measured before each sample substrate to 
confirm that the tip was not significantly modified during the sequential measurement 
of the different samples.  
 
4.3.5 Statistical analysis 
 
Refer to Section 2.3.8. 
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4.4 Results 
4.4.1 Physical adsorption studies 
 
The added 10 µM aliquot of tetracaine was completely adsorbed to Nano!"#$$% within 
15 min of mixing the drug with the particle according to the physical adsorption studies 
(Fig 4.1). The adsorption of the same concentration of drug onto the Nano!"#! was less 
rapid compared to the Nano!"#$$%, but it was still rapid and extensive. The drug 
concentration bound to the Nano!"#! gradually increased from the first time point at 15 
min (87.2 ± 4.1%) to the last time point at 48 hours (97.9 ± 0.7%). The maximum 
recovery of the drug that could be obtained from the system was 28.2 ± 4.2% and 
therefore, it was thought prudent to confirm these trends using fluorescence 
spectroscopy and AFM microscopy.  
 
4.4.2 Fluorescence studies 
 
The nanoparticles gave a small signal in the 340-420 nm region of the spectrum but as 
the particles were not fluorescent, this was probably due to the turbidity of the samples 
caused by the nanoparticles (Fig. 4.1). This small signal was subtracted from the 
measurements to focus the results on the tetracaine fluorescence. 
 
The fluorescence spectrum of Nano!"#$$% mixed with 10 µM of tetracaine displayed a 
blue shift of 21 nm, the maximum peak wavelength moved from 372 nm to 351 nm, and 
a 20-fold increase in fluorescence emission (p<0.05)(Fig. 4.2). There were no 
significant changes in the fluorescence spectra observed when Nano!"#! were added to 
the 10 µM tetracaine solution (p>0.05) despite the adsorption process that was shown to 
occur previously.   
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Figure 4.1. Fluorescence spectrum of pH 4 (A) and 8 (B) water (black) before and after 
the addition of carboxyl-modified polystyrene nanoparticles, Nano!"#$$%  (red) and 
unmodified silica nanoparticles, Nano!"#!(blue). 
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Figure 4.2. Fluorescence spectrum of 10 µM of tetracaine (TET) before and after the 
addition of carboxyl-modified polystyrene nanoparticles, ( Nano!"#$$% ) and 
unmodified silica nanoparticles (Nano!"#!) in pH 4 (A) and pH 8 (B). Peak wavelength 
and intensity showed in parenthesis.  
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4.4.3 AFM adhesion force measurements method development 
 
The commercially available gold cantilevers were selected over in-house gold-coated 
probe tips because they provided the least surface roughness (0.18 ± 0.02 nm) and 
highest signal voltage output (2V in air)(Table 4.2, Fig. 4.3 for tip image). Force 
measurements could not be determined with the in-house gold-coated cantilevers 
because the signal voltage outputs were too low to function.  
 
Coatings on cantilever 
Root mean square 
roughness (nm) 
Uncoated  2.55 ± 0.84 
Thermally evaporated gold  0.31 ± 0.03 
Thermally evaporated gold (tip side) 3.15 ± 0.46 
Sputtered gold  0.45 ± 0.05 
Sputtered gold (tip side) 0.32 ± 0.04 
Commercially available gold  0.18 ± 0.02 
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Figure 4.3. Optical images tip side of (A)(C)  and Z-piezo (B)(C) images of cantilevers 
gold coated by thermal evaporation (A)(B) and commerically available gold cantilevers 
(C)(D). 
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Figure 4.3. Optical images tip side of (A)(C)  and Z-piezo (B)(C) images of cantilevers 
gold coated by thermal evaporation (A)(B) and commerically available gold cantilevers 
(C)(D). 
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The AFM tips were modified with methyl and amine groups using the known solution 
deposition method as evident from the contact angle measurements (Table 4.3, Fig. 4.4). 
The clean hydrophilic gold surface had a zero contact angle and when placed into the 
alkane-thiol solution, the CH3-functionalised group produced a hydrophobic surface 
(>90°). The established solution deposition technique was used for the amine-
functionalized gold surface and a hydrophilic amine surface (<90°) was formed. The 
polystyrene surface had a moderately hydrophobic surface (>90°)(Table 4.3, Fig 4.4). 
 
Substrate material Contact angle (°) 
Gold  0 ± 0* 
CH3 functionalized gold surface  180 ± 0* 
Amine functionalized gold surface 0 ± 0 
Polystyrene   127.4 ± 6.1 
 
 
Table 4.3. Contact angle of flat substrates. * Surfaces are very hydrophobic. 
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Figure 4.4. Contact angle of amine-functionalised surface (left) and polystyrene surface 
(right). The amine surface is hydrophilic and spreading takes place. The polystyrene 
surface is hydrophobic, having a contact angle of 127.4 ± 6.1°.  
 
Chapter 4: A mechanistic investigation of how tetracaine adsorption onto nanoparticulate 





X. J. Cai 
130 
The CH3-CH3 force adhesion measurements taken before each sample measurement 
were not significantly different (p>0.05), thus suggesting that the tip used was not 
contaminated by the measurements or damaged during the moving between samples 
(Table 4.4). 
 
Tip interaction with CH3 substrate prior to the 
following tip-substrate interactions Ftip-CH3 (nN) 
CH3-Amine 9.19 ± 5.46 
CH3-NanoPSCOOH 9.97 ± 4.81 
CH3-Nano!"#! 9.31 ± 4.57 
CH3-PS 10.61 ± 3.86 
Amine-NanoPSCOOH 8.73 ± 5.36 
Amine-Nano!"#! 7.29 ± 5.04 
Amine-PS 9.00 ± 4.70 
 
 
Table 4.4. Average adhesion force measurements (Ftip-CH3) between CH3-functionalised 
tip and CH3-functionalised substrate prior to sample measurements taken from 10 
contact areas x 21 force curves in pH 8 water. Triplicates were performed. * Significant 
differences were observed compared to CH3-CH3 adhesion force measurements.  
 
4.4.4 AFM adhesion force measurements 
 
In the AFM measurements, methyl and ionised tertiary amine tips were used as a 
functional representative of the two ends of a charged tetracaine molecule in AFM. 
Using the methyl tip, the strength of adhesion force with the substrates were as follows: 
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Nano!"#! < CH3 = Amine = PS < Nano!"#$$%  (Table 4.5, Fig. 4.5 and 4.6 for 
histograms). The methyl tip showed a preference in terms of adhesion force with the Nano!"#$$% surface in both pH 4 and pH 8 (p<0.05). The Nano!"#! surface showed a 
lower force of adhesion with the methyl tip compared to all the other interactions 
assessed in both pHs (p<0.05).  
 




  CH3-CH3 9.19 ± 5.46 
CH3-Amine 8.27 ± 4.41 
CH3-Nano!"#$$%* 67.61 ± 45.69 
CH3-Nano!"#!* 1.52 ± 0.78 
CH3-PS 10.10 ± 2.86 
pH
 4
   CH3-Nano!"#$$%* 59.90 ± 56.24 
 CH3-Nano!"#!* 1.47 ± 1.05 
 
 
Table 4.5. Adhesion force measurements (Fad) recorded between CH3-functionalised 
tips and various substrates. The measurements were taken from 10 contact areas X 21 
force curves in pH 8 and 4 water. Triplicates were performed. * Significant differences 
were observed compared to CH3-CH3 adhesion force measurements. 
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Figure 4.5. Histograms depicting adhesion force measurements (Fad) between CH3-
functionalised tip and various substrates: (A) CH3-functionalised substrate, (B) Amine-
functionalised substrate, (C) Nano!"#$$%, (D) Nano!"#! and (E) polystyrene substrate. 
Measurements were taken from 10 contact areas x 21 force curves in pH 8 water. 
Triplicates were performed.  
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Figure 4.5. Histograms depicting adhesion force measurements (Fad) between CH3-
functionalised tip and various substrates: (A) CH3-functionalised substrate, (B) Amine-
functionalised substrate, (C) Nano!"#$$%, (D) Nano!"#! and (E) polystyrene substrate. 
Measurements were taken from 10 contact areas x 21 force curves in pH 8 water. 
Triplicates were performed.  
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Figure 4.5. Histograms depicting adhesion force measurements (Fad) between CH3-
functionalised tip and various substrates: (A) CH3-functionalised substrate, (B) Amine-
functionalised substrate, (C) Nano!"#$$%, (D) Nano!"#! and (E) polystyrene substrate. 
Measurements were taken from 10 contact areas x 21 force curves in pH 8 water. 
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Figure 4.6. Histograms depicting adhesion force measurements (Fad) between CH3-
functionalised tip and various substrates: (A) Nano!"#$$% , (B) Nano!"#! . 
Measurements were taken from 10 contact areas x 21 force curves in pH 4 water. 
Triplicates were performed.  
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The strength of adhesion force between the amine tip and the substrates had the same 
trend as those with the methyl tip (Table 4.6, Fig. 4.7 and 4.8). However, the adhesion 
force between the amine tip and Nano!"#$$% were significantly stronger in pH 8 than 
in pH 4 (p<0.05).  
 




  Amine – Amine 8.73 ± 5.36 
Amine – Nano!"#$$%* 156.26 ± 11.33 
Amine – Nano!"#!* 1.77 ± 1.18 
Amine - PS 9.53 ± 4.65 
pH
 4
   Amine - Nano!"#$$%* 86.72 ± 11.28 
 Amine – Nano!"#!* 1.74 ± 1.06 
 
 
Table 4.6. Adhesion force measurements of between amine tips and different surfaces 
taken from 10 contact areas x 21 force curves in pH 8 and 4 water. Triplicates were 
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Figure 4.7. Histograms depicting adhesion force measurements (Fad) between Amine-
functionalised tip and various substrates: (A) Amine-functionalised substrate, (B) Nano!"#$$%, (C) Nano!"#! and (D) polystyrene substrate. Measurements were taken 
from 10 contact areas x 21 force curves in pH 8 water. Triplicates were performed.  
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Figure 4.7. Histograms depicting adhesion force measurements (Fad) between Amine-
functionalised tip and various substrates: (A) Amine-functionalised substrate, (B) Nano!"#$$%, (C) Nano!"#! and (D) polystyrene substrate. Measurements were taken 
from 10 contact areas x 21 force curves in pH 8 water. Triplicates were performed. 
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Figure 4.8. Histograms depicting adhesion force measurements (Fad) between Amine-
functionalised tip and various substrates: (A) Nano!"#$$% , (B) Nano!"#! . 
Measurements were taken from 10 contact areas x 21 force curves in pH 4 water. 
Triplicates were performed.  
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4.5.1 𝐍𝐚𝐧𝐨𝐏𝐒𝐂𝐎𝐎𝐇-tetracaine interactions 
 
The physical adsorption studies suggested that tetracaine had a strong affinity with both 
the nanoparticles surfaces. However, the low recovery of tetracaine, which was 
probably a consequence of tetracaine aggregates remaining bound to the surface of the 
filter, meant that these results needed further confirmation. As a consequence, the data 
from physical absorption studies were supported by the generation of the fluorescence 
spectroscopy and AFM data.  Previous work by Mertz et al. (1990) showed that when 
tetracaine aggregates were subjected to molecules known to form hydrogen bonds, a 
fluorescence blue shift was observed. The Nano!"#$$%  completely adsorbed the 
tetracaine and generated a blue shift and it seemed reasonable to assume that, like the 
previous work, the addition of the nanoparticles caused aggregate break up of the 
hydrogen bonding involved in tetracaine self-association and resulted in surface 
adsorption to the particles (Guerin, Dumas et al., 1980; Mertz, Marques et al., 1990). 
The increase in fluorescence intensity further substantiates that tetracaine aggregates 
broke as tetracaine aggregates has been shown to generate fluorescence signal 
quenching (Chapter 2). When taken together, the blue shift and the increase in 
fluorescence intensity provided strong evidence that the tetracaine aggregates were 
being disrupted by the surface adsorption onto the nanoparticles. This supported the 
observations from the physical adsorption study. 
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According to the AFM data, the methyl and amine functional groups had strong 
electrostatic attractions to the strong negatively charged carboxyl and sulphate groups 
on the surfaces of Nano!"#$$%. The sensitivity of the amine interactions to the pH of 
the suspension vehicle provided evidence that this functionality did interact with the 
particle surface through electrostatic interactions. In addition, because the forces of 
interactions with the amine were stronger than for the methyl group, it appeared that 
although it was possible for the tetracaine to interact with the particle surfaces via with 
the methyl or amine functionalities, it was the latter which was more likely to be the 
primary means by which the drug adsorbed at the particle surface. Perhaps the methyl 
group did interact with the non-charged regions of the polystyrene surface, which was 
known to be relatively hydrophobic, to some degree. However, this type of interaction 
would be limited compared to the electrostatic interactions of the amine because of the 
low number of sites for hydrophobic interaction on the carboxyl-modified particles. The 
presence of two competing sites of interaction could be the reason why the force-
displacement measurements with the methyl functionality derived in this work were 
highly variable compared to similar measurements with the amide functionality. 
 
Despite evidence of aggregation being disrupted, the transport of tetracaine did not 
increase following the addition of Nano!"#$$% to tetracaine (Chapter 3). A possible 
explanation for this phenomenon is that the strong affinity between tetracaine and Nano!"#$$% resulted in tetracaine residing on the nanoparticle surface. Nano!"#$$% are 
unable to penetrate even the most superficial stratum corneum (Alvarez-Roman et al., 
2004a) and hence, this strong drug adsorption onto the particle surface could retard the 
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transport process by reducing the availability of free drug molecules to pass through the 
barrier. In previous studies by Wu et al. (2010), there was also little evidence of Nano!"#$$% retention on the skin surface and the model drug PMI was not released 
into the stratum corneum. A similar explanation was used when nile red fluorophores 
were shown to associate with the nanoparticles and were released only to a certain 
extent (Wu, Price et al., 2009). 
 
4.5.2 𝐍𝐚𝐧𝐨𝐒𝐢𝐎𝟐-tetracaine interactions 
 
The Nano!"#! interactions with tetracaine were weaker than the drugs interactions with Nano!"#$$%. This was demonstrated by the physical adsorption measurements, the 
absence of a shift in the fluorescence spectra of the tetracaine solution in the presence of 
the nanoparticles and the relatively low adhesion force measurements recorded in the 
AFM studies. The interaction strength of the probes with the substrates was influenced 
by the vehicle pH in the case of the amide functionality and therefore, the origin of the 
weaker attraction between and the drug and the silica particles compared to the 
carboxyl-functionalised material was considered to be the relative strength of the 
electrostatic interactions that occurred between the drug and the particle surface. 
 
There are mixed reviews on the extent of skin penetration of Nano!"#! (Iannuccelli et 
al., 2014; Nafisi et al., 2015; Rancan, Gao et al., 2012; Staronova et al., 2012) but there 
is a general consensus that Nano!"#!of more than 75 nm do not penetrate through the 
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epidermis (Rancan, Gao et al., 2012). Hence, the any drug penetration enhancement was 
most probably driven by the drug-nanoparticle interface occurring on the surface of the 
skin. Although tetracaine was not strongly bound to the Nano!"#!, the nanoparticles 
resulted in a 3.6-fold and 2.0-fold enhancement in tetracaine transport at pH 4 and pH 8 
respectively. From this data, it does not seem unreasonable to assume that the 
interactions between tetracaine and the Nano!"#!  drove the enhanced permeation 
through the porcine epidermis and silicone membrane. It is possible that the weak Nano!"#!-tetracaine interactions broke up the tetracaine aggregates and increased drug 
permeation across the skin. However, none of the analytical techniques employed in this 
work could directly investigate this highly dynamic phenomenon.  
 
By linking the analytical data with the transport studies, it was apparent that a balance 
of interaction strength between the nanomaterial surface and tetracaine was required to 
enhance membrane transport. If the interactions were too strong, this could retard 
permeation (Nano!"#$$% ), whereas a more moderate interaction could enhance 
transmembrane transport (Nano!"#!). This conclusion supports the work by Ueda et al. 
(2012), where excipient interaction-induced modification of drug aggregation was 
believed to be the reasons behind the improved permeation across a biological barrier. 
Similarly, in this project, nanoparticles were used to provide a solid interface that can 
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The data generated in this chapter supported the hypothesis generated in Chapter 3 and 
that the addition of nanoparticles to a topical pharmaceutical preparation can modify 
drug delivery into the skin through physical interactions with the particulate surface. 
The search of the right balance of interaction strength between the nanomaterial surface 
and tetracaine is important as one that is too strong can retard permeation 
(Nano!"#$$%), but one that has a moderate interaction to modify the state of tetracaine 
in a manner that can enhance transmembrane transport (Nano!"#!). It was anticipated 
that this better understanding of the mechanisms of nanomaterial enhancement of 
tetracaine transport into the skin would permit the design of effective topical 
formulations in Chapter 5.  











Topical Tetracaine Formulations 
Containing Nanomaterials to Increase 














Tetracaine is commercially available as Ametop, a 4% gel that has an onset of action of 
30 to 45 minutes (Joint Formulary Committee, online). This application time is too slow 
for optimal clinical action and this has driven formulators to design of a number of 
formulation strategies to try and improve the clinical use of this agent (Fang et al., 
2008; Fisher et al., 1998; Hu et al., 2000). However, these strategies perturb the skin 
barrier and may result in long-term damage to the skin. One reason for the long onset of 
action may be that tetracaine is an amphiphilic drug that aggregates in aqueous vehicles 
(Attwood, 1995; Schreier, Malheiros et al., 2000). The relevance of drug molecular 
aggregation on membrane permeation has been highlighted in Chapter 2, wherein the 
drug aggregates of tetracaine exhibit different physicochemical properties in solution 
compared to the non-aggregated form of the molecule and at the high tetracaine drug 
concentrations typically found in topical preparations, this physical aggregation can 
modify penetration into the skin after topical application. Although it has been shown in 
Chapter 2 that formulating tetracaine at lower concentrations reduces the aggregation 
and improves drug transport, using a low drug concentration in vivo would reduce its 
clinical effect and is therefore not a viable strategy to improve anaesthesia. It is 
however, based on data from Chapter 3 and 4, reasonable to believe that a strategy that 
could break up tetracaine aggregation using nanoparticles could improve the onset of 
anaesthesia by improving drug penetration into the tissue. 
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In Chapter 3, the introduction of silica nanoparticles enhanced drug permeation by 3.6-
fold at pH 4 and 2.0-fold at pH 8. However, rather than acting as a drug carrier, the 
solid nanomaterials, broke up drug aggregates without the particles themselves 
penetrating into the skin. This is an attractive drug delivery approach to improve the 
action of tetracaine because the added nanomaterials are unlikely to enter the body and 
hence raise additional toxicity concerns (Baroli, Ennas et al., 2007; Ryman-Rasmussen 
et al., 2006; Wu, Price et al., 2009). The data presented in Chapter 4 demonstrated that 
nanomaterials surface interactions were critical to the skin penetration enhancement 
process. However, to this point in the work, a topical formulation has not been designed 
with the purpose of enhancing percutaneous penetration simply by the addition of 
nanomaterials. 
 
It is important if attempting to include nanomaterials in a topical semi-solid product to 
consider the nanoparticle-vehicle interactions (Benaouda, Brown, Ganguly et al., 2012). 
The vehicle can influence drug percutaneous penetration by controlling the drugs 
thermodynamic activity (Watkinson et al., 2009), modifying the membrane structure 
(Cross, Pugh, et al., 2001; Dal Pozzo & Pastori, 1996) and influencing the diffusion 
coefficient of the drug through the vehicle viscosity (Radebaugh & Simonelli, 1983; 
Welin-Berger et al., 2001). Although a solvent matrix must interact with a drug to 
solubilise it, a strong interaction in a complex solvent can have a detrimental effect on 
skin permeation through changes in drug diffusion (Benaouda, Brown, Martin et al., 
2012). This is especially true if trying to increase the penetration of a drug from a 
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vehicle using nanoparticles because strong drug-vehicle interactions may influence the 
nanoparticle-drug interactions. 
 
The aim of this chapter was to assess if adding nanomaterials to semi-solid topical 
preparations could enhance drug delivery. The experiments were conducted at pH 8 
because Ametop, the commercially marketed gel, was formulated at pH 8 and the 
aggregation properties of tetracaine had been studied in previous chapters using this pH. 
Hydroxypropyl methycellulose (HPMC) was chosen as the excipient to produce a semi-
solid formulation due to its inert nature and ability to form a gel with a large pore size 
(Mohamed et al., 2015). A spray formulation was used to apply the semi-solid as this 
allowed the mixing of the nanoparticles and the drug only upon drug application, which 
avoided any physical instability issues that could reduce the homogeneity of dosing. 
The sprays were optimised in terms of spray characterisation and viscosity to ensure 
accurate dosing. Tetracaine permeation from the different formulations was then 
assessed using porcine epidermis as a skin model. Comparisons with the commercially 
available Ametop were conducted to assess the potential for the developed formulation 
to provide superior drug deposition into the skin. Two drug application protocols were 
used to dose the drug to the skin: infinite dose studies were performed to understand the 
effects of vehicle composition on tetracaine delivery; finite dose studies were carried 
out to assess the clinical relevance of any differences observed in the formulations. 
Silica nanoparticles (Nano!"#!) were used because in Chapter 3, they were shown to 
elicit the highest tetracaine enhancement effect when performed in aqueous solutions. 
Similar to the application protocol in Chapter 3, Nano!"#! were co-administered to the 
skin and no drug was encapsulated into the particles or adsorbed onto their surfaces 
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prior to administration. The semi-solid dosage form’s macroviscosity were measured 
using traditional ‘cone and plate’ rheometry to have a better understanding of the 
interactions taking place in the system, i.e., between the drug, nanoparticle and 
formulation. 
5.2 Materials 
Material Specifications Company 
Tetracaine  
 
Free base, ≥ 98% Sigma Aldrich, UK 
HPMC powder Grade 65SH viscosity 400 cP 





Nano!"#! Silica nanoparticles with a 
diameter of 200 nm (Psi-0.2) 
Kisker Biotech 
GmbH and Co., 
Germany 
 
Ametop gel 4.0% w/w tetracaine base  AAH 
Pharmaceuticals, UK 
 
Hydrochloric acid (HCl) 
 
Fuming, 37% Sigma Aldrich, UK 
Phosphate buffered saline 
  
Tablets, pH 7.4, 0.172 M Oxoid Ltd, UK 
De-ionised water 
 
Electrical conductivity 0.5-1 µS Produced in house 
Sodium acetate 
 
Anhydrous, ≥ 99% Sigma Aldrich, UK 
Acetic acid 
 
ACS reagent, ≥ 99.7% Sigma Aldrich, UK 
 
Acetonitrile High performance liquid 
chromatography (HPLC) grade 
 
Fisher Scientific, UK 
Methanol 
 
HPLC grade Fisher Scientific, UK 
Water 
 
HPLC grade Fisher Scientific, UK 
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5.3.1 Spray formulation preparation 
 
The HPMC solutions were prepared by stirring HPMC powder slowly into pH 8 water 
at 70°C and allowing the system to hydrate for 24 h at 5°C. The formulations were then 
transferred into 50 mL plastic spray bottles (Boots, UK). Three HPMC formulations 
were produced with polymer concentrations of 1% and 2% of Grade 65 (viscosity 400 
cP, 65SH400) and 3% of Grade 65 (viscosity 50 cP, 65SH50) because concentrations 
above these levels were unable to spray through the nozzle of the dosing system used to 
apply them to the skin in the permeation studies. 
 
5.3.2 Spray characterisation 
 
The spray formulation was placed at a distance of 5 cm vertically above a piece of filter 
paper and two shots of the formulation were actuated onto the paper to analyse the 
deposition characteristics of the semi-solid surface deposition. The film that was left on 
the filter paper after the formulation was sprayed onto it was outlined and the shortest 
diameter and the longest diameter of the outline were measured.  The measurements 
were used to calculate the area covered by the product based on a perfect circle 
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(Equations 5.1 and 5.2) and the aspect ratio (AR, Equation 5.3). Triplicate 
measurements were performed for each formulation. 
 D!"#$ =   !!"#!  !!"#!                                            (Equation 5.1) Area =   π !!"#$! !                                           (Equation 5.2) AR =    !!"#!!"#                                               (Equation 5.3) 
 
Ten actuations from the spray were applied to a tared weighing boat on an analytical 
balance and individually measured. The amount of formulation recovered in the nozzle 
(nnozzle) was measured by the subtraction of the initial mass of the nozzle (ninitial) from 
the final mass of the nozzle (nfinal) at the end of 10 actuations (Equation 5.4).  
 n!"##$%   =   n!"#$% −   n!"!#!$%                                                (Equation 5.4) 
 
5.3.3 Viscosity of formulation 
 
The rheological measurements were performed using CSL a cone and plate rheometer 
(Carri-med, USA) with plate diameter of 4.0 cm and cone angle of 1.5° at a 100 mm 
fixed gap. The test was performed over a 1-10 Hz frequency range at constant stress 
amplitude of 0.798 Pa. All the measurements were carried out at 20°C. Twenty data 
points were recorded for each rheogram and triplicates were performed for each 
formulation. 
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5.3.4 Tetracaine transport studies 
 
Experiments to test the penetration of tetracaine through the porcine epidermis were 
performed as described previously in Section 2.3.6. The steady state flux (J) of 
tetracaine was determined and the enhancement ratios (ER) due to the various additives 
(water or  Nano!"#!) were calculated using Equation 3.1.   
 
In the studies in this chapter, two different formulation-dosing procedures were used. 
Infinite dosing studies applied 1 mL to the Franz cell and compared a saturated 
tetracaine solution of pH 8 to a HPMC formulation (developed in the study) and the 
commercial preparation Ametop. None of the systems contained nanoparticles, as the 
objective was to understand the drug-vehicle interactions.  
 
The finite dosing tested the ability of the addition of nanoparticles on the formulations 
to deliver tetracaine into the skin. The nanoparticles were added at a concentration of 50 
mg/mL to the tetracaine formulations immediately prior to application to the skin to 
avoid any potential problems induced by chemical or physical instability. The finite 
dosing transport study used 10 µL of Ametop or 3% HPMC formulation. The exact 
weight of the donor solution applied corresponded to 4.87 and 4.85 mg/cm2 
respectively. To these two 151 mM drug-loaded gels (drug loading was matched across 
the two formulations), an equal amount (10 µL) of with silica nanoparticles (Nano!"#!) 
or water (control) were added to the formulation at the 0 h time point after correcting 
the suspension medium pH to 8. 
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5.3.5 Tetracaine quantification 
 
Refer to Section 2.3.7. 
 
5.3.6 Statistical analysis 
 
Refer to Section 2.3.8. 
  










5.4.1 Formulation optimisation and characterisation 
 
 
A high spray volume, a low amount of residual formulation in the nozzle, a large spray 
deposit area and a moderately high viscosity were all thought to be desirable product 
characteristics for the spray systems. The 2% 65SH400 was thought not to be ideal 
because it had the lowest spray actuation mass (66.7 ± 43.7 mg), highest residual nozzle 
mass after spray actuation (66.0 ± 15.3 mg), lowest mean spray deposit diameter (2.4 ± 
0.3 cm), lowest mean spray deposit area (4.5 ± 1.1 cm2) and highest viscosity (Fig. 5.1).  
 
The 1% 65SH400 and 3% 65SH50 formulations were not significantly different 
(p>0.05) in terms of the amount of spray actuated (157.7 ± 14.1 mg). However, 3% 
65SH50 was chosen for further investigation rather than 1% 65SH400 because, 
although it covered a relatively small area (5.9 ± 0.5 cm2), it showed appropriate 
viscosity to remain on the skin (Fig. 5.1) and 104-fold less residue was found on the 
nozzle (p<0.05). Furthermore, the 3% 65SH50 gel was the most efficient in terms of 
ejecting the dose of the three spray formulations. 
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1% 65SH400 2% 65SH400 3% 65SH50 
Mass of each spray actuation (mg) 157.7 ± 14.1  66.7 ± 43.7* 145.5 ± 27.5 
Amount recovered in nozzle (mg) 31.4 ± 18.2* 66.0 ± 15.3* 0.3 ± 0.1 
Dmean (cm) 3.5 ± 0.1* 2.4 ± 0.3 2.7 ± 0.1 
Area (cm2) 9.8 ± 0.6* 4.5 ± 1.1 5.9 ± 0.5 
Aspect ratio 1.0 ± 0.0 0.9 ± 0.1 0.7 ± 0.1 
 
 
Table 5.2. Characteristics of various HPMC formulations. Data represent mean ± 
standard deviation of 3 independent tetracaine samples. * Significant differences were 






















Figure 5.1. Storage modulus (G’, solid) and loss modulus (G’’, open) measured as a 
function of frequency (Hz) for various 1% 65SH400 (■), 2% 65SH400 (●) and 3% 
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5.4.2 Infinite transport studies 
 
Infinite doses of tetracaine were used to understand the effect of vehicle composition on 
tetracaine transport (Table 5.3, Fig. 5.2 for permeation profiles). According to 
manufacturer’s data, the commercially available Ametop gel consisted of 151 mM of 
tetracaine with sodium hydroxide, sodium methyl-o-hydroxybenzoate, sodium propyl-
p-hydroxybenzoate, monoboasic potassium phosphate, xanthan gum, sodium chloride 
and purified water. The HPMC formulation consisted of an equivalent concentraation of 
tetracaine with 3% HPMC. No nanoparticles were added to these systems. There was no 
significant difference (p>0.05) in steady-state tetracaine transport rate ((110.23 ± 40.93 
µg/cm2/h) and lag time (9.15 ± 2.05 min) when infinite doses of tetracaine were 
delivered by Ametop and the HPMC formulation compared to a simple saturated 
tetracaine solution, i.e. with no formulation additives. 
 
 








Tetracaine in HCl solution 110.23 ± 40.93 66.20 ± 24.58 64.5 ± 21.11 9.15 ± 2.05 
Tetracaine in Ametop formulation 105.36 ± 21.97 63.27 ± 13.19 59.80 ± 9.31 10.10 ± 1.50 
Tetracaine in HPMC formulation 107.28 ± 28.31 64.43 ± 17.00 67.19 ± 18.21 8.79 ± 2.43 
  
 
Table 5.3. Steady state flux and permeability constants, kp, accumulative mass at 45 
minutes, m45min, and lag time, tlag, of infinite dosages of Ametop and tetracaine HPMC 
in the presence of different additives in pH 8 across porcine epidermis membrane. Data 
represent mean ± standard deviation of 3 independent tetracaine samples. * Significant 
differences were observed based on one-way ANOVA. 
  































Figure 5.2. Permeation profiles of infinite dosages of tetracaine in HCl solution (■), 
Ametop formulation (●) and HPMC formulation (▲) in pH 8 across porcine epidermis. 
Each point represents the mean ± standard deviation, n=5. The straight lines represent 
the steady-state portion of the permeation profiles. 
 
5.4.3 Finite transport studies 
 
Finite studies were performed to study the transport of tetracaine from the semi-solid 
formulations using a dosing regime that matched clinical conditions (Table 5.4, Fig. 5.3 
and 5.4 for permeation profiles of HPMC and Ametop formulations respectively). 
Based on manufacturer’s data, the   Nano!"#!, which were added to the formulations, 
only consisted of amorphous silica and water. Thus, water acted as a control to mimic 
the drug dilution effects that were experienced upon addition of the nanoparticles to the 
formulation.  
















Ametop  1.16 ± 0.14 - 0.25 ± 0.06 31.60 ± 3.00 
Ametop + water 5.62 ± 2.25 4.71 ± 1.40* 2.53 ± 1.77* 20.20 ± 1.34* 
Ametop + Nano!"#! 14.19 ± 2.27 12.86 ± 3.16* 8.12 ± 1.21* 10.69 ± 1.98* 
HPMC 46.99 ± 7.96 - 31.13 ± 4.04 7.09 ± 1.80 
HPMC + water 30.51 ± 12.16 0.69 ± 0.35 21.99 ± 10.48 3.97 ± 1.07* 
HPMC + Nano!"#!  109.95 ± 28.63 2.48 ± 1.08* 76.83 ± 18.92 * 2.02 ± 0.79* 
 
Table 5.4. Steady state flux, flux enhancement ratio, ER, accumulative mass at 45 min, 
m45min, and lag time, tlag, of finite dosages of Ametop and tetracaine HPMC in the 
presence of different additives in pH 8 across porcine epidermis membrane. Data 
represent mean ± standard deviation of 3 independent tetracaine samples. * Significant 
differences were observed based on one-way ANOVA. 
 
Calculation of the lag time showed that the HPMC spray, with the added Nano!"#! , had 
the shortest permeation lag time (tlag)(2.02 ± 0.79 min). In addition, the tetracaine 
permeation rate (109.95 ± 28.63 µg/cm2/h) and the amount of tetracaine permeating at 
the 45 min time point (m45min)(76.83 ± 18.92 µg) were the highest when tetracaine was 
formulated as the HPMC spray containing the  Nano!"#!. The addition of water to the 
HPMC semi-solid formulation did not induce a significant change in tetracaine steady 
state flux (30.51 ± 12.16 µg/cm2/h) and m45min (21.99 ± 10.48 µg), but it did induce a 
1.7 times reduction in tlag from 7.09 ± 1.80 min to 3.97 ± 1.07 min. (Table 5.4, Fig. 5.3 
for permeation profiles). Compared with the water control, the Nano!"#! significantly 
enhanced (p<0.05) percutaneous tetracaine transport 3.6-fold when added to the HPMC 
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formulation (Table 5.4). In addition, the Nano!"#!significantly increased m45min by 


























Figure 5.3. Permeation profiles of Ametop (■) with the addition of water (●) and 
unmodified silica nanoparticles, Nano!"#!(▲), in pH 8 across porcine epidermis. Each 
point represents the mean ± standard deviation, n=5. The straight lines represent the 
steady-state portion of the permeation profiles. 
 
In contrast to the HPMC formulation, the addition of water to the Ametop formulations 
significantly enhanced tetracaine permeation rates by 5-fold, increased accumulative 
mass by 10-fold and reduced tlag by 1.5 times (Table 5.4, Fig. 5.4 for permeation 
profiles). Compared to the water control, the Nano!"#!  addition to the Ametop 
formulation increased the skin permeation by 2.7. However, of the two formulations 
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tested, the HPMC formulation was superior. It significantly enhanced the tetracaine flux 
(46.99 ± 7.96 µg/cm2/h) by 40-fold, increased accumulative mass (31.13 ± 4.04 µg) by 























Figure 5.4. Permeation profiles of tetracaine in HPMC formulation (■) with the 
addition of water (●) and unmodified silica nanoparticles, Nano!"#!(▲), in pH 8 across 
porcine epidermis. Each point represents the mean ± standard deviation, n=5. The 
straight lines represent the steady-state portion of the permeation profiles. 
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5.4.4 Rheology of formulations 
 
The rheological characteristics of the semi-solid formulations were examined to try and 
further understand the observed differences in the tetracaine permeation profiles (Fig. 
5.5). All the Ametop formulations were significantly (p<0.05) more viscous (higher 
storage and loss modulus) than the HPMC formulations. The addition of water in both 
formulations significantly decreased (p<0.05) the viscoelasticity of the formulations. 
However, there were no significant changes (p>0.05) in rheological behaviour when the 






































Figure 5.5. Storage modulus (G’, (A)) and loss modulus (G’’, (B)) measured as a 
function of frequency (Hz) for Ametop (■), Ametop with the addition of water (n), 
Ametop with the addition of silica nanoparticles, Nano!"#! (★), HPMC formulations 
(▼), HPMC formulation with the addition of water (◇), formulation with the addition 
of Nano!"#! (✕). Data points represent mean ± standard deviation, n=3.  










Efficient release of a drug from a topically applied formulation is essential for topical 
preparations administered to the skin because of the highly resistant barrier that the 
cutaneous membrane provides. One reason why topical corticosteroid preparations elicit 
side effects, such as skin thinning, is that large doses are required on the surface of the 
skin due to the inefficient release of drug. For example, an investigation by Shah et al. 
(1989), only 5-10% of the applied hydrocortisone was released from commercial 
creams. To circumvent this problem, more effective topical administration vehicles are 
required, but the type of formulation vehicle must be matched to the issues presented by 
the drug. For example, Reid et al. (2013) showed that EtOH/PEG HFA spray could 
generate a 6-fold enhancement of BMV delivery through the skin as compared to 
commercial cream. However, Fiala et al. (2015) demonstrated that a similar approach 
when trying to improve the skin penetration of lidocaine compared to the commercial 
product was not successful. Therefore, a topical vehicle must be constructed with the 
issues of the drug in mind. 
 
In the previous chapters, tetracaine was shown to interact with silica nanoparticles to 
break up its aggregates and improve permeation into the skin. However, this data was 
generated in simple solutions, which facilitated analytical characterisation of the 
system, but these systems could not be used clinically. Topical formulations need to 
exhibit a degree of viscosity and therefore, viscosity modifiers, such as xanthan gum 
and HPMC, are often incorporated into the topical system. Improved viscosity can 
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increase product acceptance by the patient, because it is easy to use, it adheres to the 
treated area, spreads well and have a good consistency. Viscosity is also an important 
consideration in the manufacturing process of the product. However, viscosity modifiers 
may hinder drug diffusion from the formulation into the skin. For example, the addition 
of a 7% gelling agent to thicken a Transcutol:isopropyl myristate binary mixture 
resulted in a four-fold decrease in clebopride diffusion (Rhee et al., 2007). The decrease 
was attributed to the increased viscosity of the gel formulation.  
 
To investigate the possible effects of the added viscosity modifiers in this study, infinite 
dose studies were used. The infinite dose studies provided a mechanistic insight to 
investigate the effect of vehicle composition on drug delivery, as no nanomaterials were 
added to these systems. The data demonstrated that neither the xanthan gum or HPMC 
had a large effect on tetracaine permeation behaviour, i.e. the excipients were 
considered to be relatively inert. The influence of HPMC on drug permeability is 
dependent on its viscosity and this is critical in governing the drug-HPMC interactions. 
When higher concentrations of HPMC are used in a topical formulation, the polymer is 
known to show a bigger effect on the drug, even reducing drug permeability. For 
example, in supersaturated conditions, HPMC acts as an anti-nucleating agent, 
interacting with the drug to prevent nucleation (Iervolino et al., 2000; Megrab et al., 
1995; Raghavan et al., 2000). However, when lower concentrations of HPMC have 
been used in the literature, similar observations have been made that were similar to the 
data generated in the current work (Charoo et al., 2008; Kim et al., 2001).  
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To investigate the clinical utility of the tetracaine HPMC spray formulation, finite 
dosing studies were conducted. There is often a significant difference between infinite 
finite dose studies. For example, in a study by Cross et al. (2001), thickening agents 
were shown to retard drug penetration through the skin in infinite dose studies but the 
opposite effect was observed in finite dose studies. The authors attributed the different 
results to the increased hydration due to less water evaporation and enhanced drug 
diffusivity through the stratum corneum when using finite doses. The difference in drug 
permeation behaviour between the HPMC gel and the commercial preparation in this 
study may be related to the manner in which the two high molecular weight molecules 
in the formulations alter the viscosity of the preparations. Xanthan gum is considered to 
be a non-gelling agent, whereas HPMC forms a gel (Mughal et al., 2011). When there is 
an infinite amount of drug applied to the skin, there is a little increase in the formulation 
viscosity but in the finite studies, there is a significant change in formulation viscosity 
due to the small amount of preparation applied to the skin. It may be that the HPMC 
system can resist the changes in viscosity upon application to the skin in finite 
conditions such that it does not alter the drug diffusion through the preparation, 
compared to the Ametop preparation. In the HPMC preparation, there is the possibility 
that changes in the macroviscosity of the polymer may not translate into the diffusional 
characteristics of molecules passing through the gel as the polymer produces a gel-like 
network. However, in the case of Xanthan gum, the changes in macroviscosity were 
proportional to the changes in viscosity experienced by the diffusing molecules.  
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In the present study, the nanomaterials were added on the skin just after application of 
the formulation and so, in order to generate comparative data in the control systems 
employed in the work, an equivalent amount of pH-adjusted water was used to match 
the volume modification effect of adding the nanoparticle suspensions to the semi-solid 
preparations. When the systems with and without nanomaterials were compared across 
both types of semi-solid vehicles used in this work, the nanomaterials enhanced drug 
permeation into the skin. Based on these results and the particle-drug interaction data 
from the previous chapter (Chapter 4), it was assumed that the drug permeation 
enhancement induced by the addition of the Nano!"#!was caused by the breaking up of 
the tetracaine aggregates due to weak surface interactions between Nano!"#! and the 
tetracaine molecules.  
 
According to the rheological data, there was no difference between the viscoelasticity of 
the semi-solid formulations upon the addition of water and silica particles. This was 
unlike the results obtained by Moddaresi et al. (2010), where an increase in 
viscoelasticity was observed when lipid nanoparticles were added to hyaluronic acid 
vehicle. In the previous work, they attributed the change in rheological behaviour to the 
presence of strong interactions between the nanoparticles and the hyaluronic acid. In the 
current study, the rheology data implied that the formulation excipients and the 
nanoparticles did not generate a strong interaction. Thus, any change in the tetracaine 
permeation was largely due to the other interactions taking place in the system, i.e. 
tetracaine-nanoparticle and tetracaine-formulation interactions. This was supported by 
the fact that the enhanced permeation was observed both in the in-house manufactured 
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HPMC formulation and the commercially available Ametop preparation even though 
the two preparations exhibited very different rheological behaviour. 
 
The addition of the liquid to the tetracaine formulations, regardless of whether or not the 
liquid contained nanoparticles, altered the drug permeation through the skin. Large error 
bars were encountered when liquid was added to the semi-solid systems, most probably 
due to the lack of mixing during application and/or due to the non-homogenous 
presence of nanoparticles within the drug in the gel. Nevertheless, a viscosity-dependent 
permeation behaviour was observed. This is not always the case with other preparations 
reported in the literature. It is possible for a semi-solid system to exhibit a viscosity-
independent permeation behaviour (Gallagher & Heard, 2005; Suh & Jun, 1996). 
However, when a viscosity-dependant permeation behaviour is observed, it is more 
typically akin to the work by Pygall et al. (2011), who showed that meclofenamate 
aggregates formed hydrogen bonds with the HPMC, leading to an increase in the 
viscosity of the formulation and subsequently a decrease in drug release from HPMC 
structures. The data from the current study showed the opposite effect. This may have 
been because of the relatively strong drug-drug affinity of the tetracaine molecules 
(CAC – 7.38 µM as shown in Chapter 2) and the weak interactions between the drugs in 














An efficient tetracaine topical spray formulation with superior drug permeability and a 
more rapid onset of action compared to commercial Ametop was generated. This was 
obtained through the addition of nanoparticles to a semi-solid preparation that were 
sprayed onto the skin. Nanoparticles were thought to have disrupted the tetracaine 
aggregates, which retarded the drug permeation and hindered lag time. The HPMC 
spray formulation was thought to be superior to the commercial preparation due to the 
lower macroviscosity, which allowed the tetracaine to be more readily available to 
permeate through the skin. However, the addition of nanoparticles to the commercial 
formulation was also effective in improving the delivery of tetracaine, which suggests 
that this novel drug delivery strategy could even be applied to currently marketed 
products to enhance their performance. 
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Topical drug delivery to the skin presents an attractive alternative to other routes of 
administration by providing a non-invasive strategy that bypasses the first-pass 
metabolism, reduces the adverse side effects of systematic toxicity and improves patient 
compliance (Brown, Martin et al., 2006). However, efficient topical delivery can be 
problematic to achieve due to the relative impermeability of the stratum corneum 
(Scheuplein & Blank, 1971). Many enhancement strategies have been employed to 
overcome this problem (Hadgraft, 1999) and one such approach is the use of 
nanomaterials.   
 
Nanomaterials in topical products can enhance the percutaneous penetration of 
therapeutic agents (Alves et al., 2007; Borgia et al., 2005; Chen et al., 2006). In 
particular, solid nanomaterials greater than 20 nm (the size most regularly employed in 
drug delivery studies) are an attractive formulation additive because they are too large 
to pass into the skin and hence, they probably will not illicit drug toxicity effects 
(Baroli, Ennas et al., 2007; Ryman-Rasmussen et al., 2006; Wu, Price et al., 2009). 
Despite the numerous reports documenting the ability of nanomaterials to enhance drug 
permeation across the skin, the mechanisms by which they do this remain less well 
defined. The literature has generated some general hypotheses of how nanomaterials aid 
topical skin delivery, including carrying the drug across the barrier (Alvarez-Roman et 
al., 2004a) and modifying the skin barrier (Wissing, Lippacher et al., 2001). 
Interestingly, there does not seem to be previous reports that have specifically aimed to 
enhance drug penetration into the skin using nanoparticle surfaces to modify the 
physical interactions of drugs applied topically to the skin. As such, the aim of the 
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thesis was to elucidate the interactions in drug-nanomaterial formulations and generate a 
dynamically triggered formulation that enhances drug permeation. It was hypothesised 
that the introduction of the nanoparticles at the point of administration would generate a 
dynamic system that could break up drug-drug aggregation in a manner that could 
enhance drug percutaneous penetration. 
 
Tetracaine was selected as a model drug in this study because it is known to form 
aggregates and its commercially available preparation (Ametop 4% gel) has an onset of 
action of 30-45 minutes (Joint Formulary Committee, online).  This long onset of action 
has previously been suggested to be a consequence of tetracaine’s aggregation 
properties (Inacio, Barlow et al., In-press). Therefore, the deliberate perturbation of 
molecular aggregation would appear to be a sensible means to enhance topical drug 
delivery of this molecule.  
 
In order to enhance the penetration of tetracaine into the skin, its skin permeation 
characteristics required further understanding (Fig. 6.1). Given the small size and 
dynamic nature of aggregates, direct analysis of the structures of monomers and 
aggregates was considered difficult when the molecules are at concentrations and in 
vehicles that are appropriate for pharmaceutical use. As the ‘context’ of the drug was of 
vital importance when direct analytical characterisation was impossible, indirect 
approach was employed to try to understand the aggregate structure and the functional 
consequences of aggregation in liquids that could be used for drug administration.  
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Tetracaine was shown to form a series of different aggregates across the µM 
(fluorescence spectroscopy) to mM (light scattering analysis) concentration range and 
this was paramount to enable a better understanding of how the drug presented itself to 
the surface of a biological barrier after topical application. The aggregate formation 
process was demonstrated to be sensitive to the pH of the vehicle in which the drug was 
dissolved in due to the modification of tetracaine’s ionisation. As the pH increased, the 
CAC decreased (pH 4, CAC – 11 µM; pH 8 CAC – 7 µM). A similar phenomenon was 
observed by Attwood and Natarajan in 5 different piperazine drugs (Attwood & 
Natarajan, 1981). It was suggested from the data that the types of aggregates formed 
varied in the different pH solutions due to the different ionisation environment of the 
molecules. In a water vehicle buffered at pH 8, unionised tetracaine molecules were 
thought to be trapped in a hydrophobic environment while in a pH 4 vehicle, charged 
aggregates were more likely to be formed. In both the pHs, hydrogen bonding was 
thought to govern the self association because previous work has shown that tetracaine 
molecules stack via 𝑁 − 𝐻⋯𝑁 tertiary association with some 𝑁 − 𝐻⋯𝐶 = 𝑂 ester 
and 𝑁 − 𝐻⋯𝑁 − 𝐻  bonds (Guerin, Dumas et al., 1980). 
 
The drug permeation data generated in Chapter 2 of the thesis demonstrated that the 
different presentation of tetracaine aggregates on the membrane had a significant impact 
upon the drug’s percutaneous penetration. When porcine epidermis was used for the in 
vitro assessment of tetracaine transport through the skin at pH 4, concentration-
dependent aggregation decreased the permeability of tetracaine. When silicone 
membrane was employed as the barrier, the trends in the porcine skin were mirrored and 
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this suggested that follicular route, which was only present in the porcine skin, was not 
playing a significant role in drug transport. This eliminated the possible hypothesis that 
the reduction of permeability of tetracaine could be caused by the saturation of the 
appendages by both the charged aggregates and non-aggregates. Therefore, it was 
suggested that only non-aggregated molecules drove the tetracaine transport and the 
formation of the more polar aggregates formed in pH 4 were reducing the proportion of 
membrane diffusing species passing through the skin via the intracellular or 
transcellular pathway, consequently decreasing the permeability of tetracaine. 
 
At pH 8, the formation of uncharged aggregates due to the increase in tetracaine 
concentration increased the permeability of tetracaine across the skin. One possible 
hypothesis that could explain such a phenomenon is that drug aggregation increases the 
affinity of the drug to the skin. It was suggested that both non-aggregated and 
aggregated molecules drove the tetracaine transport at this pH and the more 
hydrophobic aggregates formed were actually contributing in some means to the 
membrane diffusing species. This relationship between drug aggregation and 
permeation suggested that controlling the aggregation of drugs could be a novel means 
to modulate transport through the skin (Fig. 6.1). 
 
Drug aggregation can be perturbed by the addition of substances that compete for drug-
drug association sites. Theoretically, these substances can include counter-ions 
(Attwood & Udeala, 1975), surfactants (Darwent, McCubbin et al., 1982; Rossetti, 
Lopes et al., 2011; Shao, Li et al., 1993; Spikes & Bommer, 1986) and polymers 






X. J. Cai 
175 
(Pygall, Griffiths et al., 2011); all of which can disrupt drug-drug interactions via 
competitive interaction. However, in this PhD project, the addition of a high 
concentrations of negatively charged dihydrogen phosphate electrolytes (1:10000 
tetracaine to phosphate ratio) had no effect to the fluorescence emission and transport 
rates of tetracaine, which suggested that tetracaine-tetracaine aggregation could not be 
disrupted by the relatively weak ion-pair interactions that were formed between the 
negatively charged phosphate and the positively charged drug in pH 4 environment. In 
contrast, the introduction of nanomaterials was able to modify drug aggregation (Fig. 
6.2).  Negatively charged carboxyl-modified polystyrene nanoparticles (Nano!"#$$%) 
and silica nanoparticles (Nano!"#!) were used to represent two different nanoparticle 
surfaces with which the model drug tetracaine could interact, thereby generating very 
different tetracaine transport profiles. When tetracaine was mixed with Nano!"#$$%, 
the particles prevented the drug’s penetration through both the porcine and silicone 
barriers. On the other hand, the Nano!"#!  generated a 3.6-fold and a ca. 100-fold 
enhancement in tetracaine percutaneous penetration across porcine epidermis and 
silicone membrane respectively at pH 4. The higher permeation enhancement ratio at 
pH 4 (3.6-fold) compared to at pH 8 (2.0-fold) may be attributed to drug aggregation 
and their contribution to drug permeation. At pH 4, the addition of Nano!"#! may break 
up the non-permeating aggregates in a manner that could facilitate the temporal increase 
in drug monomers that could permeate across the skin while at pH 8, the modification 
of already permeating aggregates led to an increase, but not one as high as at pH 4. 
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Nanomaterial-induced drug enhancement across hydrophobic membranes has been 
reported in the literature (Alves et al., 2007; Borgia et al., 2005; Chen et al., 2006) and 
this effect was replicated in the data reported in this work. However, what was novel 
about the work in this study was that the transport was assessed upon the dynamic 
mixing of a solid nanoparticle and a drug on the membrane surface to which it was 
administered. This was unlike conventional usage of the nanoparticle as a drug carrier, 
where drug is encapsulated within the nanoparticle.  
 
To understand more about the nanoparticle surface-drug interactions, the instant mixing 
of the drug with nanoparticles upon the barrier and the prior equilibration of the system, 
i.e. the incubation of drug and nanoparticles for a period of time (30 days), was 
compared. In both systems, the Nano!"#$$% had a negative effect on the permeability 
of tetracaine, i.e. no tetracaine across the membrane was quantified. The equilibrated Nano!"#!-tetracaine system that was incubated for 30 days and the dynamic Nano!"!! - 
tetracaine system that was mixed on the surface of the skin both gave impressive 
enhancement effects when measuring transport across the silicone membrane. The 
direct mixing of the drug and nanomaterials on the surface of the skin was the preferred 
application method as it minimised any potential interference from chemical or physical 
instability as a consequence of forming the mixture. Thus, this dynamic mixing was 
used throughout this study. 
 
As the Nano!"#$$% contained SDS, it was thought beneficial to test the effects of this 
additive. However, SDS did not appear to significantly alter tetracaine transport. 
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Conversely, the soluble silica available in the aqueous phase of the Nano!"#! 
suspension played a role in enhancing tetracaine transport. This may have arisen due to 
ion-pairing, but the major benefit in terms of penetration enhancement still appeared to 
arise due to the presence of the nanoparticle surfaces according to the comparison of the 
different systems permeation rates. These results emphasised the importance of the solid 
interface provided by the nanoparticles (not the oppositely charged ions, equilibration 
time, carrier or vehicle) to perturb tetracaine aggregation demonstrated by the change in 
tetracaine permeation.  
 
The reason why Nano!"#$$%  and Nano!"#!  generated such very different tetracaine 
transport profiles was examined through a detailed investigation of the drug-
nanoparticle surface interactions that occurred on the skin surface once the topical 
formulations had been applied to the skin. The particle drug interactions were monitored 
using physical adsorption studies, fluorescence spectroscopy and atomic force 
microscopy force adhesion measurements. Methyl and ionised tertiary amide tips were 
used as a functional representative of the two ends of a charged tetracaine molecule in 
AFM studies.  
 
The Nano!"#$$% interactions with the drug were relatively strong. This was evident 
from the physical adsorption studies, the blue shift in the fluorescence measurements, 
and the high strong force adhesion measurements. The Nano!"#$$% has carboxyl and 
sulphate surface groups and therefore, the interaction with the tetracaine, which has at 
least one positive charge (it can have two positive charges depending on the solution 
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pH), was anticipated to be mainly via electrostatic forces. The amine functionality on 
the tetracaine was thought to be the primary means by which the drug adsorbed at the 
particle surface, as the force-adhesion measurements between tetracaine and the amine 
group were stronger than the drug interactions with the methyl group. These 
observations implied that tetracaine aggregates were disrupted by the drug surface 
adsorption onto the nanoparticles. However, these strong interactions resulted in 
tetracaine being retained on the nanoparticle surface and because the Nano!"#$$% are 
unable to penetrate even the most superficial stratum corneum (Alvarez-Roman et al., 
2004a), the strong drug adsorption onto the particle surface retarded the drug transport 
across the skin. A similar explanation was suggested in a previous study to explain why Nano!"#$$%  did not release their drug payload into the stratum corneum (Wu, 
Landfester et al., 2010). 
 
Tetracaine had a weaker affinity with Nano!"#! than Nano!"#$$% as demonstrated by 
the physical adsorption measurements, the absence of a shift in the fluorescence spectra 
of the tetracaine solution in the presence of the nanoparticles and the relatively low 
adhesion force measurements recorded in the AFM studies. This reduction was 
attributed to the lower surface charge of the Nano!"#! (ca. – 20 mV) compared to the Nano!"#$$%   (ca. -40 mV), which diminished to some degree the electrostatic 
interactions between positive amine of tetracaine and the negative particle surface. 
Despite the weak surface adsorption of tetracaine on to the particles, the Nano!"#! still 
resulted in a 3.6-fold and 2.0-fold increase in drug transport across the skin at pH 4 and 
8 respectively. It is possible that the weak Nano!"#!-tetracaine interactions broke up the 
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tetracaine aggregates and increased drug permeation but did not retain the drug for long 
periods on the particle surface. This conclusion supports the work by Ueda et al. (2012), 
where drug-excipient interactions-induced modification of drug aggregation modified 
drug permeation across a biological barrier.  
 
By linking the analytical data with the transport studies, it was apparent that a balance 
of interaction strength between the nanomaterial surface and tetracaine was required to 
enhance membrane transport (Fig. 6.2). If the interactions were too strong, this could 
retard permeation (Nano!"#$$%), whereas a more moderate interaction could enhance 
transmembrane transport (Nano!"#!).  
 
The new understanding of the mechanism of nanomaterial-induced percutaneous 
enhancement enabled the design of a topical nanoparticle containing gel formulation 
that exhibited an improved permeation profile compared to the commercial formulation. 
The gel was administered to the skin as a spray, which was optimised in terms of spray 
characterisation and viscosity to ensure accurate dosing. The commercial comparator 
was Ametop. Both formulations were compared with and without the addition of Nano!"#! . For comparative purposes, the tetracaine concentration in the HPMC 
formulations was matched to Ametop (4% w/w) and studies were conducted at pH 8. 
Two drug application protocols were used to dose the drug to the skin: infinite dose 
studies were performed to provide a mechanistic insight into the possible effects of 
vehicle composition on tetracaine delivery; finite dose studies were carried out to assess 
the clinical relevance of any differences observed in the formulations. 
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Finite dosing of the formulations to the porcine epidermis generated the fastest drug 
permeation, highest accumulative mass at 45 min and shortest lag time when the HPMC 
tetracaine spray was combined with silica nanoparticles (Nano!"#!). When compared to 
the commercial Ametop, the spray formulation enhanced tetracaine transport by 95-
fold, improved accumulative mass by 307 times and reduced the lag time by 15.6-fold 
(Fig. 6.3). This enhancement was mainly attributed to the tetracaine-nanoparticle 
interactions. The Nano!"#! enhanced percutaneous tetracaine transport by 3.6-fold and 
2.7-fold in the HPMC formulation and Ametop formulation respectively when 
compared to the water control. In addition, in both formulations, the Nano!"#!increased 
the accumulative mass at 45 min by approximately 3 times and reduced the lag time by 
about 2-fold when added to the HPMC formulation as compared to the water control. 
Based on these results and the drug-Nano!"#! interaction data obtained previously, it 
was assumed that this enhancement induced by the Nano!"#!was due to the breaking up 
of tetracaine aggregates facilitated by the weak surface interactions between the Nano!"#!and the tetracaine molecules.  
 
According to the infinite dose studies, the excipients (HPMC in the in-house spray or 
the xanthan gum present in the Ametop) did not significantly change the tetracaine 
permeation behaviour and were considered to be relatively inert. Similar observations 
were reported by Kim et al. (2001) and Charoo et al. (2008). The addition of liquid to 
both the tetracaine formulations altered the drug permeation through the skin but the 
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major effect arose from the addition of  Nano!"#!. Furthermore, there was no difference  
 
between the viscoelasticity of the semi-solid formulations upon the addition of water 
and Nano!"#!, implying that formulation excipients and the Nano!"#! did not generate a 
strong interaction. This was contrary to the investigation by Moddaresi et al. (2010), 
where strong interactions between lipid nanoparticles and hyaluronic acid in the form of 
an increase in viscoelasticity were reported. Thus, any change in the tetracaine 
permeation was largely due to the other interactions taking place in the system, i.e. 
tetracaine-nanoparticle and tetracaine-formulation interactions.  
 
HPMC-based formulation exhibited superiority over Ametop in terms of drug 
permeation enhancement – it improved the tetracaine flux by 40-fold, increased 
accumulative mass by 124-fold and reduced lag time by 8-fold, as compared to the 
Ametop formulation. The two gel forming systems were very different, with Ametop 
using xanthan gum as a viscosity modifier, which primarily influenced both the micro 
and macroviscosity of the formulation, while HPMC only influenced the latter. 
However, as mentioned earlier, nanoparticle effects are independent of the formulation 
vehicle. Thus, even though the rheology data demonstrated that changing the viscosity 
of the formulation vehicle influenced the percutaneous penetration of tetracaine, this 
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From the thesis, it can be concluded that aggregation influences passive percutaneous 
skin permeation. Aggregation can occur in low concentrations and thus, it is not 
surprising that it will be prevalent in amphiphilic commercial products. Given that 
aggregation can hinder penetration into the skin after topical application, it may even be 
the cause of the slow onset of action and low penetrating amount of tetracaine observed 
in drugs. Studies using other amphiphilic drugs may provide more evidence to support 
this hypothesis.  Currently, the investigation of molecular aggregation was conducted 
by indirect inference of the spectroscopic data. The development of a more direct and 
sensitive method could enable a more accurate conclusion to be made between drug 
aggregation and its percutaneous penetration. 
 
Using the data in the thesis, it can also be concluded that nanomaterials could be added 
to a topical preparation after the loading of a drug into the system in order to enhance 
administration through the control of the drug aggregation process. This mechanism 
was demonstrated by the examination of drug-nanoparticle surface interactions. This 
examination was limited by the small surface area of the drug molecules and large 
surface area of the nanoparticles. As such, inferences about the interactions of tetracaine 
and the nanoparticles were made between the functional groups of both surfaces without 
taking consideration into the surface geometry or whole drug molecule properties. It 
would be preferable if a technique that probes these interactions more accurately were 
used. 
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Finally, it was concluded from the thesis that a HPMC using the nanoparticle 
technology to deliver tetracaine was found to be superior to a commercial product 
delivering the same drug. This demonstrates that this topical formulation can be used to 
produce clinical products. Further studies should be conducted to investigate the system 
using human skin in vitro experiments and using animals in vivo to explore the potential 
of generating a product that can be applied to humans. In addition, the minimum drug to 
nanoparticle ratios that could enhance the drug percutaneous penetration would help to 
reduce the material costs to manufacture this product. In order to facilitate patient 
compliance, the silica nanoparticles can also be introduced in a semi-solid formulation 
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